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ABSTRACT

Bovine adipose-derived stem cells (ADS), a form of adult stem cells, are
somatic cells that have similar characteristics of embryonic stem (ES) cells.
Bovine ADS cells possess multipotent capabilities and have been found to
express pluripotency genes associated with ES cells. The unique properties of
ADS cells make them a desirable source for reprogramming experiments. The
goal of reprogramming experiments is to transform somatic cells from a
differentiated state to a pluripotent state. When somatic cells reprogram, there
are certain epigenetic changes or modifications that must occur in order to
successfully reprogram the nucleus. Epigenetic modifications will change the
chromatin configuration without changing the DNA sequence. Somatic cells can
be exposed to small molecules that may be able to reduce the chances of having
incomplete chromatin modification. Two epigenetic modifying factors are a DNA
methyltranferase inhibitor, zebularine (Zeb), and a histone deacetylase inhibitor,
valproic acid (VPA). By inducing gene expression with the epigenetic modifiers,
the cells may be stimulated to reprogram more efficiently than cells with lower
gene expression.
In the first experiment, three bovine ADS cell lines were treated with VPA
or Zeb to observe the changes in expression levels of Oct4, Sox2, and Nanog
(pluripotency-associated genes). The cells were treated for a period of 5, 7,10,
or 14 days. VPA led to the highest increase of the pluripotency genes; however,
both treatments may have produced a partial reprogramming. This partial
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reprogramming may result in the bovine ADS cells reaching complete
pluripotency when combined with a reprogramming technique.
In the second experiment, three bovine ADS cell lines were treated with
VPA or Zeb for five days then followed with transduction using lentivirus. Oct4,
Sox2, and Nanog were increased the highest when using epigenetic modifiers.
Statistical differences for expression of the pluripotency-associated genes were
found for cells treated with zebularine. While it was thought that viral
transduction in combination with epigenetic modifiers would produce higher
expression levels of the pluripotency-associated genes, this was not found to be
true in this experiment.
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CHAPTER I
INTRODUCTION
A growing field in today’s clinical research is regenerative medicine.
Regenerative medicine uses stem cells or pluripotent cells to regenerate and
repair damaged tissue. Stem cell regenerative medicine can potentially reverse
dysfunctional or damaged cells caused by disease or injury (Odorico et al.,
2001). Stem cells are the ideal cell for regenerative medicine based on their
distinctive qualities, and the cells are able to constantly regenerate, while
maintaining the capability to differentiate into multiple cell lineages when induced
in culture (Bunnell et al., 2008). There are two main types of stem cells used for
this purpose, embryonic stem (ES) cells and adult stem cells. ES cells originate
from the inner cell mass of blastocysts (Martin, 1981), and they are able to form
the three germ layers of the embryo (endoderm, mesoderm, and ectoderm)
(Evans and Kaufman, 1981). Because ES cells are difficult to isolate and
harvest, recipient rejection, contamination, and tumor production, adult stem cells
have been considered. Some sources of adult stem cells are adipose tissue,
cartilage, and bone marrow. Adipose stem cells have been isolated and
characterized (Zuk et al., 2002; Gimble and Guilak, 2003; Bunnel et al., 2008),
and like adipose stem cells in humans, bovine adipose stem cells were found to
differentiate into chondrocytes, osteoblasts, and adipocytes (Picou, 2009). The
experiments conducted in this study, focus on producing less differentiated or
pluripotent cells to use as donors for nuclear transfer (NT). We hope to further
modify adult stem cells to make them more readily reprogrammable by NT.
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In the first experiment, bovine adipose-derived stem (ADS) cells were
treated with epigenetic modifiers and observed for changes in expression levels
of pluripotency-associated genes. We hypothesize that these ADS cells could be
reprogrammed to a more pluripotent state. If somatic cells contained pluripotent
qualities, they could potentially differentiate into cells of the three germ layers
that generate an embryo or certain cell types. Three lines of bovine ADS cells
were treated with valproic acid (VPA), a histone deacetylase inhibitor, or
zebularine (Zeb), a DNA methyltransferase I inhibitor, for 5, 7, 10, or 14 days at
which point quantitative RT-PCR was conducted.
In the second experiment, bovine ADS cells were treated with epigenetic
modifiers for 5 days before being infected with a lentivirus containing
transcription factors for Oct4, Sox2, Klf4, and c-Myc. Cells were cultured for 1416 days for colony growth before being passaged a second time once colony
formation was detected. For both experiments, morphology and expression of
Oct4, Sox2, and Nanog gene transcripts was observed. Our hypothesis was that
with pretreatment of cells with epigenetic modifiers, transduction of bovine ADS
cells with lentiviral particles would produce a more pluripotent cell.
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CHAPTER II
LITERATURE REVIEW
Stem Cells
Over the years, interest in stem cells has intensified due to the cells’
unique characteristics. Stem cells are capable of indefinite self-renewal;
however, they still have the capability to transform into specialized cells (Martin,
1981). When stem cells transform into another cell type, the action is defined as
differentiation (Odorico et al., 2001). Stem cells can undergo multi-lineage
differentiation (Bunnell et al., 2008), meaning that these cells can become a
specialized cell type from multiple lineages (such as bone or fat) when induced in
certain culture conditions.
There are two main types of stem cells, embryonic stem cells and adult
stem cells. Embryonic stem (ES) cells are cells that are present in an embryo
before they differentiate into the three germ layers that form the embryo (Evans
and Kaufman, 1981). Adult stem cells, the second type of stem cells, can be
found in adult tissues. In an adult, stem cells are mainly for repairing and
maintaining the adult tissues (Odorico et al., 2001). While ES cells can
differentiate into any cell type, most adult stem cells can differentiate into a range
from one specialized cell to many specialized cell types (Sell, 2005). ES cells’
distinctive ability to potentially differentiate into any of the three germ layers is
defined as pluripotency. The major reasons for research on stem cells are to
utilize their abilities to constantly renew themselves, to be cultured over multiple
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passages at an undifferentiated state, and to differentiate into specific cell types
(Stocum and Zupanc, 2008).
Stem cells can be isolated and cultured for use in research. They can be
isolated from the embryo or adult tissue to establish cell lines of embryonic stem
cells or adult stem cells, respectively. The main incentive for conducting
research on stem cells is their potential roles in reparative or regenerative
medicine. The ability of the cells to differentiate into specific cell types is
desirable for medicinal research. Stem cells may be used to repair injured
tissues in patients with irreparable injuries or diseases (Takahashi and
Yamanaka, 2006). Another suggestion is to use stem cells to better understand
cellular functions such as DNA methylation or histone acetylation (Stocum and
Zupanc, 2008). DNA methylation and histone acetylation are involved in embryo
differentiation. Stem cells can have various uses in research because of their
ability to be isolated and maintained in culture.
Embryonic Stem Cells
ES cells originate from the inner cell mass of blastocysts (Martin, 1981).
As the ES cells in the inner cell mass differentiate, they are able to form the three
germ layers of the embryo (endoderm, mesoderm, and ectoderm) (Evans and
Kaufman, 1981). Because of this ability to differentiate into the three germ
layers, ES cells are defined as being pluripotent. Another unique characteristic
of ES cells is their capability of infinite self-renewal in culture (Odorico et al.,
2001; Stocum and Zupanc, 2008).
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ES cells were not isolated or cultured until 1981. Evans and Kaufman
(1981) were able to isolate ES cells from mouse blastocysts and establish a cell
line as a pluripotent tissue culture. When a blastocyst was plated, the inner cell
mass from the mouse blastocyst formed egg shaped like structures inside of the
growing trophoblast cells. Pluripotent cells found in the inner cell mass of the
blastocyst were observed to produce ES cells (Evans and Kaufman, 1981). In
the same year, ES cells were discovered to form into a wide range of cell types
and formed teratomas when injected into mice (Martin, 1981). The cells were
determined to contain characteristics similar to teratomacarcinoma cells. Martin
et al., (1981) designated the cells derived from the inner cell mass ES cells.
When cultures of the ES cells were allowed to develop into embryoid bodies, a
variety of differentiated cell types were found in culture (Martin, 1981). The
ability to form embryoid bodies that contain multiple differentiated cell types from
the three germ layers makes the cells derived from the inner cell mass
pluripotent.
Despite the observance of mouse ES cells, human ES cells were not
isolated until 1998. Cells were isolated from embryos from in vitro fertilization
(IVF) that were cultured to the blastocyst stage. The inner cell mass was
revealed to produce cell lines that had similar morphology to reported ES cells in
primates (Thomson et al., 1998). The lines that were established had normal
karyotypes, expressed high levels of telomerase activity, expressed alkaline
phosphatase, and expressed cell surface markers similar to those expressed by
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nonhuman primate ES cells and human embryonal carcinoma cells (Thomson et
al., 1998).
The ability of ES cells to differentiate into all three germ layers was an
incredible discovery and led to a huge spark in interest in studying embryonic
stem cells (Thomson et al., 1998). The inner cell mass was found to be similar to
the totipotent zygote nucleus in its ability to produce a developed blastocyst and
embryo (Illmensee and Hoppe, 1981). This statement has since proven to be
false because ES cells cannot differentiate into the placenta. The zygote is
totipotent, forming the whole embryo and placenta; however the blastocyst
contains the inner cell mass and the trophectoderm. The trophectoderm will
become the placenta and the inner cell mass will become the embryo. The he
absence to form the extra-embryonic structures makes them pluripotent rather
than totipotent. Pluripotent cells were recorded to be present in the mouse
embryo until the early pre-implantation stage (Evans and Kaufman, 1981). When
the inner cell mass is grown on irradiated mouse embryonic fibroblasts (MEF),
ES cells can be cultured and maintained (Stocum and Zupanc, 2008).
Potential Problems with Embryonic Stem Cells
Stem cells are the driving force behind regenerative medicine.
Regenerative medicine is based on using stem cells or pluripotent cells that can
regenerate or repair damaged tissue. Diseases or injuries involved in
dysfunction and damage of cells are potentially treatable with stem cell
regenerative medicine (Odorico et al., 2001). All regenerative therapies rely on
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ES cells or adult stem cells (Stocum and Zupanc, 2008). Within regenerative
medicine, stem cells or artificial tissues produced from stem cells must be
transplanted or implanted into the patient in order to attempt to repair the
damaged tissue. An ideal source of stem cells would be one that does not
produce an immune rejection response by the patient (Sun et al., 2009). While
stem cells have the potential to change the scientific world with the regenerative
medicine, the cells do pose some problems in practice.
There are a few obstacles that need to be considered and observed
before stem cells can be used in regenerative medicine or research applications.
First, stem cells have potential problems in regenerative medicine because it is
difficult to isolate an optimal amount of cells to be used in therapy (Sun et al.,
2009). They are also difficult to harvest, and are prone to differentiate when
grown in culture (Stocum and Zupanc, 2008). A second problem with the use of
stem cells in regenerative medicine is recipient rejection (immune rejection) once
the stem cells are injected (Takahashi and Yamanaka, 2006). Third, ES cells
pose the possibility of contamination from the mouse embryonic fibroblasts
feeder layers (Sun et al., 2009). A fourth problem is the undifferentiated stem
cells have been shown to produce tumors when injected into immunodeficient
mice (Martin, 1981; Stocum and Zupanc, 2008). This poses many threats and
hesitation to using ES cells in medicine. Last, there is a problem with isolating
the ES cells from a blastocyst. In order to extract embryonic stem cells from a
blastocyst, the embryo must be destroyed (Yu et al., 2007). This creates many
ethical obstacles with using human ES cells.
7

Because of the controversy surrounding the use of ES cells, it is crucial to
find other options to acquire cells that are similar to ES cells. The first option is
to utilize adult stem cells, which can be isolated from adult tissue (Sun et al.,
2009). A second option is reprogramming differentiated cells to become ES celllike. Reprogramming somatic cells can produce cells that are morphologically
and characteristically similar to ES cells (Takahashi and Yamanaka, 2006). This
process of reprogramming cells can also be helpful to understand the regulation
of cell differentiation (Stocum and Zupanc, 2008). While ES cells can be
potentially devastating to use in medicine because of the cells’ potential to
produce immune rejection and tumors, a close alternative can be produced if
adult stem cells or induced pluripotent stem cells are used.
Adult Stem Cells
Bone marrow transplants have been performed for over 40 years, but it
was not until later on that bone marrow cells were discovered to be adult stem
cells. Woddliff first described bone marrow isolation and characteristics of the
cells in 1964. Bradley and Metcalf (1965) were able to observe colony formation
when culturing mouse bone marrow cells on kidney and embryo feeder layers.
While at the time the bone marrow cells were not thought to be stem cells, they
were later discovered to contain hematopoietic stem cells (HSCs) and
mesenchymal stem cells (MSCs) (Kuznetsov et al., 1997; Tropel et al., 2006).
Furthermore, human MSCs from bone marrow were observed to differentiate
exclusively into adipocytes, chondrocytes, or osteocytes when isolated and
expanded (Pittenger et al., 1999). Pittenger et al., (1999) discovered human
8

MSCs were able to proliferate extensively, but still possessed the ability to
differentiate into various cell types. These reports were important in paving the
way to discover adult stem cells.
Adult stem cells are cells that are present in adult differentiated tissue.
When animals need to regenerate certain tissues, they usually activate their adult
stem cells and cause them to differentiate into the needed tissues (Stocum and
Zupanc, 2008). Adult stem cells can be found in adipose tissue, cartilage, and
bone marrow to name a few sources. Human adipose tissue is an abundant
source of cells with an ability to provide large numbers of cells (Gimble and
Guilak, 2003). Adipose stem cells have been previously isolated and
characterized (Zuk et al., 2002; Gimble and Guilak, 2003; Bunnel et al., 2008).
The adipose stem cells collected from humans were discovered to possess the
ability to differentiate into multiple lineages making them multipotent (Bunnel et
al., 2008). Later in 2009, bovine adipose stem cell isolation and characterization
was described. Like adipose tissue in humans, bovine adipose stem cells were
found to differentiate into chondrocytes, osteoblasts, and adipocytes (Picou,
2009).
An advantage to using adipose adult stem cells (contradicting with normal
adult stem cells) is the easy isolation and large quantity of cells that can be
obtained (Sun et al., 2009). This makes adult stem cells a desirable source for
stem cell research because of the need for patient specific cells. Adult stem
cells, such as adipose stem cells, can be isolated from people of all ages (Sun et
al., 2009). The adipose stem cells are a reliable source for hundreds of million
9

cells from an individual (Gimble and Guilak, 2003). Adipose stem cells are
developed from mesenchymal cells, and are multipotent as opposed to
pluripotent because they have a limited number of specialized cells that they can
become (Gimble and Guilak, 2003; Bunnell et al., 2008). Liposuction is a
commonly performed surgery, and the adipose tissue is always discarded (Sun
et al., 2009). Adipose stem cells can be isolated from the adipose tissue
immediately after extraction, and the adipose tissue can provide enough cells for
medical applications (Sun et al., 2009). The popularity of the fairly non-invasive
procedure, abundance of discarded tissue, and ease of isolation of the stem cells
make adipose stem cells an optimal cell choice for medical practices (Gimble and
Guilak, 2003; Sun et al., 2009).
Reprogramming Somatic Cells
The main objective behind reprogramming somatic cells is to produce
cells that are like ES cells. Having pluripotent characteristics means that the
cells will be able to form the three germ layers of the embryo (endoderm,
mesoderm, and ectoderm) (Evans and Kaufman, 1981). The term somatic cell
refers to cells of the body, excluding germline cells.
Somatic cells have been examined for years for their ability to reprogram
to a totipotent or pluripotent state. Somatic cells were thought to have
irreversible cell nuclei that could not reprogram from their determined cell fate
(Hochedlinger and Jaenisch, 2006). Differentiated cells are cells that have
reached a specialized cell type, with some having reached their final cell fate.
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The process that occurs when a cell becomes a more specialized cell type is
called differentiation. The ability of a differentiated cell to reprogram to a
totipotent or pluripotent state has mainly been observed using nuclear transfer
procedures. More recently however, differentiated cells have been shown to
reprogram to a pluripotent state when utilizing viral vector transduction. This
method first described using a retrovirus containing four transcription factors that
are involved in maintaining pluripotency in ES cells (Takahashi and Yamanaka,
2006). Takahashi and Yamanaka designated the cells with acquired pluripotent
capabilities as induced pluripotent stem cells (iPS). Differentiated cells have
been successfully reprogrammed by nuclear transfer (Briggs and King, 1952;
Gurdon et al., 1958; Illmensee and Hoppe, 1981; Wilmut et al., 1997), direct
reprogramming with viral vectors (Takahashi and Yamanaka, 2006; Takahashi et
al., 2007; Wernig et al., 2007; Yu et al., 2007; Lowry et al., 2008; Carey et al.,
2009), fusion with ES cells (Cowan et al., 2005), and exposure to ES cell extracts
(Hochedlinger and Jaenisch, 2006).
Reprogramming a somatic cell in amphibians was first performed by
nuclear transplantation (Briggs and King, 1952). In 1952, a protocol for
transferring a nucleus from a differentiated cell into an unfertilized ovum with an
extracted nucleus had not been reported. The first hurdle was to create a
protocol for nuclear transplantation. The protocol, reported by Briggs and King
(1952), was designed to create minimal damage to the embryo while extracting
and injecting the nuclei. Briggs and King (1952) wanted to test nuclei of
differentiated cells to examine if the nucleus itself became differentiated as the
11

embryonic cells differentiated. A frog ovum was enucleated and the amphibian
late blastula (embryonic) cells were used to provide the extracted nucleus. The
ability of the cells to differentiate was observed by determining the cells ability to
form an embryo. If complete differentiation could in fact occur, this would mean
the donor cell was not irreversibly differentiated. The donor nuclei were able to
produce cleaved ova and embryos, producing 52.8% cleaved ova with 31.9%
ova producing blastulae out the ova that were enucleated and injected with a
donor cell (Briggs and King, 1952). These results demonstrated that the
transplanted nucleus of a donor cell, could in fact replace the ovum nucleus in an
enucleated unfertilized ovum when used in nuclear transfer.
Briggs and King (1952) were the first to report success in nuclear
transplantation. They discovered that donor nuclei from late blastocysts were
able to produce embryos, however if a nucleus from an older embryo (around the
gastrula stage) was used, embryos had abnormal development. John Gurdon et
al., (1958) used nuclear transplantation to produce embryos in frogs (Xenopus
laevis) from reprogrammed differentiated cells. The embryos with transplanted
donor nuclei were able to produce normal tadpoles that were able to go through
normal metamorphosis, become sexually mature, and have similar growth rate
and sexual differentiation to the controls (Gurdon et al., 1958). As the donor cells
matured to an older stage, the proportion of creating embryos from the
transplanted embryos decreased. In the study, a total of 77 metamorphosed
frogs were obtained from 2,594 nuclear transfers (Gurdon et al., 1958). This
report was able to demonstrate that a nucleus from a differentiated cell,
12

transplanted into an ovum, is able to complete normal development. The
differentiated cells must have the same genome as undifferentiated cells
because of their ability to produce viable embryos, however the cells will perform
different functions when at different stages in development. With this discovery,
cells could be examined at different stages of development for their ability to
reprogram.
Finally, mammalian somatic cells have been shown to have an ability to
reprogram to produce a viable embryo. The first reprogrammed mammalian
somatic cells were achieved in 1981 (Illmensee and Hoppe, 1981). Mouse
oocytes, used in nuclear transfer, were injected with either trophectoderm or
inner cell mass nuclei. The oocytes injected with inner cell mass nuclei produced
96 cleaved oocytes with 48 reaching a late pre-implantation stage (Illmensee and
Hoppe, 1981). Out of 16 transferred embryos, three live mice were born from the
oocytes injected with inner cell mass nuclei. This report was important because
it revealed that nuclei of mammalian cells could be reversed. Next, the results
were important because they are one of the first to examine the characteristics of
the cells of the inner cells mass. Additionally, Wilmut et al. (1997) were the first
to report a viable offspring from nuclear transfer with a differentiated adult cell
from an ewe. The donor cells were adult mammalian cells from a six year-old
ewe. This experiment was able to reveal that somatic cells from a mammal,
other than mice, were able to reprogram (Wilmut et al. 1997). These reports
establish that somatic cells are reversible regarding genetic modifications. The
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differentiated cells are in fact able to reprogram to a totipotent state and produce
live offspring when used in nuclear transfer.
Wilmut et al., (1997) were able to pave the road for further experiments
using reprogrammed differentiated cells. With the discovery of somatic cells’
ability to reprogram with nuclear transfer, the nuclei were observed to have a
reversible genome able to create a viable embryo. This discovery was able to
bypass the immunorejection and ethical issues concerning ES cells (Stocum and
Zupanc, 2008). The differentiated nucleus of a somatic cell is able to reprogram
to a totipotent state in order to de-differentiate to produce a viable offspring. The
nuclei of the somatic cells have been shown to reprogram when induced by
injecting them into an enucleated unfertilized oocyte.
While nuclear transfer is an acceptable procedure for producing
transgenic animals or multiple clones of a superior animal, the procedure has
some drawbacks. Nuclear transfer produces ethical concerns in regards to
producing copies of a particular individual, which will prevent it from being
accepted for use in human medicine. Another disadvantage in nuclear transfer is
the low reprogramming efficiencies and low viable offspring numbers. The
percentage of embryos that live to term is very low at 2-10%; this is not including
the high postnatal deaths that also occur (Rideout et al., 2001). The low
efficiencies and ethical concerns will keep nuclear transfer from becoming a
routine clinical procedure (Odorico et al., 2001). These aspects have led to a
need for a more acceptable procedure to produce pluripotent cells, such as the
use of induced pluripotent stem cells.
14

Induced Pluripotent Stem Cells
A major focus and popular topic in human medicine today is induced
pluripotent stem cells. These cells are somatic cells, not pluripotent, are
reprogrammed to possess pluripotent capabilities, and have been referred to as
induced pluripotent stem cells (Takahashi et al., 2007). Induced pluripotent stem
(iPS) cells have quickly sparked the interest of the medical and scientific
communities. The significance of iPS cells has impacted reparative or
regenerative medicine, which results in customized transplantation therapy
(Wernig et al., 2007). A goal of reparative medicine is to be able to repair
damaged tissue, such as a spinal cord, on a patient using the patient’s own cells.
This technique would reduce the risk of immune rejection and would avoid the
use of ES cells (Yu et al., 2007). A way to produce these patient specific ES celllike cells is to induce the person’s extracted and isolated cells to become
pluripotent by viral vector transduction. Another way to utilize iPS cells is to
generate iPS cells from patients with genetic diseases and investigate the
disease or development new drug treatments (Park et al., 2008). While direct
reprogramming (or viral vector transduction) creates cells that are like ES cells in
differentiation capabilities, the mechanism of actually producing the cells is still
unknown. However the process is a different reprogramming process than that
involved in somatic cell nuclear transfer (Stocum and Zupanc, 2008).
The viral vector system used to create iPS cells consists of plasmids
containing transcription factors that will infect 293T cells. The plasmids will
assemble a virus inside of the 293T cells, and the viral particles will then lyse the
15

293T cells. Next, the viral particles (collected from the culture medium) can be
treated on the target cells to result in integration of the viral vectors into the cells’
genomes. The factors should cause endogenous expression of the cells’ own
genes to result in the cells having pluripotent capabilities.
The viral vectors used when inducing the somatic cells contain
pluripotency transcription factors that are expressed in ES cells early in
development. In order to create this system, the transcription factors must first
be selected, isolated, and integrated into the plasmids and viral vectors. In order
to determine the transcription factors responsible for inducing pluripotency in
somatic cells, Takahashi and Yamanaka (2006) tested 24 factors. The retroviral
infection was tested by the ability to select for a specific selection agent, which
would result in the iPS cells becoming resistant to the agent. When all 24 factors
were used in the retroviral infection on mouse embryonic fibroblasts, resistant
colonies were formed. iPS cells were morphologically similar to ES cells,
exhibiting a round shape, large nucleoli, and little cytoplasm (Takahashi and
Yamanaka, 2006).
Next, the 24 genes were narrowed down to 10 transcription factors vital to
producing induced pluripotent stem cells. When only these 10 genes were used
in retroviral infection, more cell colonies were formed than when 24 genes were
utilized (Takahashi and Yamanaka, 2006). This then provided a pool of 10
factors, which could be examined and narrowed down further to determine their
importance in pluripotency by subtracted them one by one. No colonies were
formed when Oct4, Klf4, or c-Myc was removed, but Sox2 removal resulted in a
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few resistant colonies (Takahashi and Yamanaka, 2006). The only difference
was found in c-Myc removal producing colonies that were not similar to ES cells.
The genes essential to pluripotency were discovered to be Oct4, Sox2, Klf4, and
c-Myc (Takahashi and Yamanaka, 2006).
Morphology alone however, cannot determine a comparable similarity
between iPS cells and ES cells. Therefore, quantitative RT-PCR must be
performed in order to determine the presence and levels of expression of ES cell
markers. Many of the ES cell marker genes were found to be expressed in
higher concentrations in the pluripotent cells compared to the ES cells in the
study performed by Takahashi and Yamanaka (2006). The promoters for Oct4
and Nanog were also discovered to have increased histone acetylation and
decreased demethylation (Takahashi and Yamanaka, 2006). Last, iPS cells
were also tested for their ability to form teratomas when injected into nude mice.
The teratomas contained cells from all three germ layers, and one line of iPS
cells could result in differentiation into all three germ layers after 30 passages
(Takahashi and Yamanaka, 2006).
This report was a turning point, and scientifically ground breaking. The
ability to produce iPS cells, and the fact that the iPS cells were indistinguishable
from ES cells attracted the attention of many. Somatic cells had previously been
shown to reprogram to a totipotent state using nuclear transfer (Wilmut et al.,
1997), but now it was possible to reprogram somatic cells towards pluripotency
without destroying embryos.
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After Takahashi and Yamanaka (2006) reported the successful
reprogramming of mouse cells with the four factors, the next step would be to
examine human somatic cells for their ability to become pluripotent after viral
infection. A retroviral transduction system was used in order to create induced
pluripotent cells similar to the first experiment. The human dermal fibroblasts
were introduced to a green fluorescent protein (GFP) along with the amphotropic
retrovirus containing Oct4, Sox2, Klf4, and c-Myc (Takahashi et al., 2007).
Expression of the green fluorescent protein would mean that the cells had
reprogrammed. Despite the observations in mouse cells, less than 20% of the
infected human dermal fibroblast expressed GFP (Takahashi et al., 2007). Since
the reprogramming efficiencies were so low, a mouse receptor for the retrovirus
was introduced into the human dermal cells and the cells were called HDFSlc7a1 (Slc7a1 being the receptor). A mouse receptor was needed in the human
dermal cells to bind the mouse Oct4 transcription factor in the amphotropic
retrovirus. The human iPS cells (originally HDF-Slc7a1 cells) were similar to
human ES cells in morphology, growth, and differentiation in certain culture
conditions (Takahashi et al., 2007).
The iPS human cells were found to express markers observed in ES cells
as high as or equivalent to the expression found in ES cells (Takahashi et al.,
2007). To determine the infected cells pluripotent characteristics, the cells were
allowed to form an embryoid body and then differentiate in culture. This resulted
in differentiated cells from all three germ layers. Additionally, the question arose
on somatic cells’ reaction to the viral system. The retrovirus was also able to
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result in the reprogramming of human neonate fibroblasts and primary human
fibroblast-like synoviocytes to a pluripotent state (Takahashi et al., 2007).
The reports by Takahashi and Yamanaka (2006, 2007) sparked a huge
interest and shift in research to focus on creating iPS cells. These reports are
important to establish iPS cell characteristics and direct reprogramming
protocols. The iPS cells in the experiments were altered somatic cells that were
similar to ES cells in morphology, proliferation, gene expression, promoter
activities, and differentiation. Scientists began working to produce pluripotent
stem cells in their own labs. Mouse embryonic fibroblasts (MEF) and mouse tailtip fibroblasts were shown to develop pluripotent characteristics when using a
similar retrovirus containing Oct4, Sox2, Klf4, and c-Myc (Wernig et al., 2007).
The colonies were observed to be similar to ES cell colonies by gene expression
analysis using selection of colonies that expressed Oct4 and Nanog. The cells
were able to form the three germ layers of an embryo (Wernig et al., 2007).
Lowry et al., (2008) followed the new trend as well, and were able to create
human pluripotent cells from human dermal fibroblasts. A viral system containing
the four factors was used to infect the human dermal fibroblasts like the previous
reports. After infection with the retrovirus containing Oct4, Sox2, Klf4, c-Myc and
NANOG, colonies similar to human ES cells were observed, and normal human
ES cell markers were expressed (Lowry et al., 2008).
Oct4, Sox2, Klf4, and c-Myc are referred to as the “Yamanaka four
factors”, and they previously were thought to be the only factors that could
produce pluripotent stem cells. While Oct4, Sox2, Klf4, and c-Myc have been
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shown to be able to produce iPS cells when used in a viral system (Takahashi
and Yamanaka, 2006, 2007), pluripotency can be achieved when using Oct4,
Sox2, NANOG, and LIN28 (Yu et al., 2007). A lentiviral vector was used with the
four factors to treat human fibroblasts. A lentivirus is a virus that can infect
dividing and non-dividing cells. The experiment resulted in pluripotent cells that
could differentiate into all three germ layers, and had similar morphological
characteristics and a gene expression to ES cells (Yu et al., 2007). This study
was important to establish the role that other transcription factors play in
producing and maintaining pluripotent cells. Although Oct4 and Sox2 have been
found to be essential in formation of pluripotent stem cells, LIN28 was found to
be unnecessary for the initial reprogramming but it can increase reprogramming
frequency when present (Yu et al., 2007). Oct4, Sox2, Klf4, and c-Myc or Oct4,
Sox2, LIN28 and NANOG can induce epigenetic reprogramming to a pluripotent
state by causing a change to the DNA expression rather than to the DNA
sequence (Wernig et al., 2007). Park et al., (2008) collected dermal fibroblasts
or bone marrow-derived mesenchymal cells from genetic disease patients for
example, Parkinson disease, Huntington disease, Down syndrome, and juvenileonset, type I diabetes mellitus to generate iPS cells using the “Yamanaka four
factors” or three factors (excluding c-Myc). These cells could be used to
generate cells that can be observed for the disease characteristics along with
drug therapy.
Despite the major advances made with iPS cells, there is still an issue with
the number of plasmids needed to construct the viral vector. Carey et al., (2009)
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stated that the use of multiple proviral integrations (a single vector for each
factor) could lead to insertional mutagenesis. This mutagenesis can greatly
compromise the use of iPS cells in regenerative medicine. In order to decrease
the number of vectors, the four factors need to be in one vector. Previously,
common practice was to have one vector per factor, which would lead to multiple
proviral copies, integration of oncogenes, and reactivation of silenced viral
transcripts (Carey et al., 2009). To avoid these deleterious effects, a vector was
constructed containing the four factors (Oct4, Sox2, Klf4, and c-Myc) that were
separated by three different 2A (P2A, T2A, and E2A) peptides (Carey et al.,
2009). The plasmid was used to construct viral particles, and then the particles
were used to infect MEF and mouse tail tip fibroblasts. The levels of Oct4 and
Sox2 in the iPS cells were similar to those of ES cells (Carey et al., 2009).
Teratomas (differentiating into all three germ layers) were formed when the iPS
cells were injected into immunodeficient mice. While the efficiency in this
experiment was low (0.0001%), this single polycistronic vector can reprogram
somatic cells and help in simplifying the infection mechanism (Carey et al.,
2009).
Now that the ability to produce human and mouse pluripotent cells from
fibroblasts has been reported (Takahashi and Yamanaka, 2006, 2007; Wernig et
al., 2007; Yu et al., 2007; Lowry et al., 2008; Carey et al., 2009), it is important to
look at other somatic cells for their ability to reprogram to a pluripotent state.
Fibroblasts are the most common cell types used in reprogramming studies;
however, it takes weeks to culture and establish before being able to treat them
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with viral particles. Sun et al., (2009) showed a great alternative to fibroblasts
with the use human adipose stem cells to produce iPS cells. Human adipose
stem cells (collected by lipoaspiration) were able to reprogram two fold as fast
and 20-fold more efficient when using a lentivirus containing Oct4, Sox2, Klf4,
and c-Myc (Sun et al., 2009). The pluripotent cells could differentiate into cells of
the three germ layers, and the iPS cells expressed pluripotency markers similar
to ES cell expression (Sun et al., 2009). Importantly, human adipose stem cells
can be cultured on Matrigel, eliminating the possibility MEF contamination. This
report was one of the first to compare adipose stem cells to the normally used
fibroblasts cells. It showed the potential of adipose stem cells in the viral vector
infection procedures.
Induced pluripotent stem (iPS) cells have been produced in humans and
mice, but there is little evidence of iPS cells produced in any other mammals.
Finally, in 2009, iPS cells were produced in another mammal, porcine (Ezashi et
al., 2009; West et al., 2009). Four lentiviral vectors containing human genes for
Oct4, Sox2, Klf4, and c-Myc were used to infect porcine fetal fibroblasts, which
resulted in a reprogramming efficiency of 0.1% (Ezashi et al., 2009). The
colonies were found to be similar to ES cell in morphology (Ezashi et al., 2009).
Also, porcine mesenchymal cells derived from bone marrow were infected with
lentiviral vectors containing POU5F1, NANOG, SOX2, LIN28, KLF4, and C-MYC
to produce induced pluripotent stem cells (West et al., 2009). West et al., (2009)
took their experiment a step further and injected the pluripotent stem cells into
pre-implantation stage embryos to produce chimeric offspring. The production of
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a chimeric offspring tested the induced porcine stem cells’ pluripotent
capabilities. These reports lead to a hope that the success with iPS cells found
in porcine cells can be discovered in other mammalian cells as well.
Some problems with iPS cells however are evident. The cells have a low
reprogramming rate of less than 0.3%, and take longer than other methods to
completely reprogram (Stocum and Zupanc, 2008). This makes the viral
infection reprogramming a slow and inefficient process (Huangfu et al., 2008).
Another major problem with iPS cells is the use of oncogenes as transcription
factors in the viral system. The retrovirus-transduced oncogenes provide huge
barriers to utilizing the induced cells in reparative medicine (Wernig et al., 2007).
The known oncogenes are c-Myc and Klf4, and they can pose huge threats when
used in the viral system (Huangfu et al., 2008). The integration of the known
oncogenes into the genome of the target cells limits the use of the cells in
research and clinical studies (Yu et al., 2009). In order to produce an iPS cell
line to be used in therapy it could take up to two years because of the needed
testing to make sure the cells would not form cancerous tumors when injected
(Stocum and Zupanc, 2008). Another issue is the lack of research done on iPS
cells. There has been little research conducted on transplanted iPS cells will act
in the body over long periods of time, and questions such as whether the cells
will lose their capability to renew themselves in response to an injury have yet to
be answered (Stocum and Zupanc, 2008).
Recently, scientists have strived to correct some of the problems
aforementioned to reduce some of the hesitation of using the iPS cells in
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medicinal practices. iPS cells have been created without c-Myc in mouse and
human fibroblasts (Nakagawa et al., 2008). This has been achieved by using
transcription factors Oct4, Sox2, NANOG, and LIN28 (Yu et al., 2007).
Pluripotent cells have also been generated without c-Myc in mouse embryonic
fibroblasts (MEF) by using a histone deacetylase inhibitor, which improved the
reprogramming ability by 50-fold as compared to the controls infected only with
the three factors (Huangfu et al., 2008). While several groups have successfully
produced iPS cells without c-Myc, the time it took to reprogram the cells was
much longer compared to the time the procedure required when c-Myc was
present (Wernig et al., 2008). Removing c-Myc from the viral vectors reduces
the probability of tumor producing iPS cells. Another significant advancement
was made when Huangfu et al., (2008) were able to produce induced pluripotent
stem cells from primary human fibroblasts without using Klf4 or c-Myc. They
utilized a histone deacetylase inhibitor to reach their results. Other attempts
have been made to produce pluripotent stem cells without viral vectors. These
methods use plasmids alone to transfect the target cells, however they still use
integration of c-Myc and Klf4 (Okita et al., 2008). One study resulted in the
derivation of human iPS cells from non-integrating episomal vectors (Yu et al.,
2009). iPS cells were also created from MEF by treating the cells with
recombinant proteins (Zhou et al., 2009). The recombinant proteins used were
the four factors, and they were also able to create pluripotent cells when using
recombinant proteins for Oct4, Sox2, and Klf4 with the use of a histone
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deacetylase inhibitor. By avoiding potential integration of the known oncogenes
into the target cells, the possibility of utilizing iPS cells in medicine is rising.
Chromatin Modifications of Reprogrammed Cells
Given that the generation of patient-specific stem cells can bypass the
practical and ethical issues concerned with ES cell use (Carey et al., 2009),
inducing somatic cells to become pluripotent has great potential in research
applications. Understanding how somatic cells reprogram is a crucial first step
toward improving reprogramming efficiency. It has been proposed that the low
number of viable embryos produced in somatic cell nuclear transfer is a result of
incomplete nuclear reprogramming (Rideout et al., 2001). Incomplete epigenetic
reprogramming is considered the primary reason for developmental failure of NT
embryos (Li et al., 2003). Epigenetic changes refer to heritable changes in gene
function without causing a change to the DNA sequence (Kiefer, 2007). The
chromatin will change but the original DNA sequence will not. Chromatin
configurations that physically change the DNA are controlled by histones. Eight
histones are enveloped with small fragments of DNA in an area that is called the
nucleosome (Stocum and Zupanc, 2008).
Epigenetic reprogramming, discussed above, is a result of DNA
methylation and histone acetylation. These modifications will result in changes to
the chromatin configuration. The somatic cell nuclei must undergo epigenetic
reprogramming in order to successfully reprogram to a pluripotent state. When
cells are grown in vitro, it has been observed that they will show a change in
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levels of DNA methylation (Allegrucci et al., 2007) and histone acetylation over
time (Giraldo et al., 2007). Histone acetylation and DNA methylation need to be
studied in order to better understand their role in epigenetic modifications of the
developing embryos and differentiated cells. Cells can be treated with small
molecules that can inhibit the chromatin-modifying enzymes to reduce the
chances of having incomplete chromatin modification (Stocum and Zupanc,
2008). Manipulating the nuclear modifications with inhibitors may produce higher
reprogramming efficiencies.
In gametes DNA methylation is high, but after fertilization the embryo will
become demethylated (Yang et al., 2007). Methylation patterns must be erased
before the embryo implants to facilitate the establishment a new methylation
pattern (Rideout et al., 2001). During cleavage, DNA undergoes demethylation
followed by inherited remethylation patterns between implantation and
gastrulation (Ovitt and Schöler, 1998; Blelloch, et al., 2006). In an adult, mature
cells have a high level of DNA methylation. In order for a somatic cell to
reprogram efficiently, the DNA must be demethylated and then remethylated.
The DNA is methylated by DNA methyltransferase I transferring a methyl group
onto the fifth position of a cytosine on the CpG dinucleotide (Kiefer, 2007). CpG
islands regulate the methylation of gene expression (Allegrucci et al., 2007).
DNA methyltransferases, or DMNTs, induce silencing by interfering with the
transcription factors ability to bind the DNA and by recruiting co-repressor
complexes that contain histone deacetylases or histone methyltransferases
(Kiefer, 2007). DNA methylation results in chromatin becoming compacted.
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When DNA is methylated gene expression is repressed, resulting in the gene
being silenced.
Reprogramming efficiencies of nuclear transfer embryos have been
previously described as very low. This can be due to an inability of the embryos
to reprogram the injected donor cell nuclei. Nuclear transfer oocytes have been
observed for their ability to develop when injected with donor cells possessing
low DNA methylation or high DNA methylation. It was observed that when donor
cells had hypomethylated DNA, a higher number of embryos developed (Giraldo
et al., 2008). An inhibitor of DNA methylransferase I can be used to treat the
cells as another way to produce lower DNA methylation levels and higher
reprogramming efficiencies. Blelloch et al., (2006) used an inhibitor of DNA
methyltransferase I on neural stem cells to analyze whether treating the donor
cells first with the inhibitor would result in higher reprogramming. The blastocysts
obtained were then explanted onto MEF to observe the production of ES cell
lines by the neural stem cells. The neural stem cells produced an average
efficiency of 64% from the 22 neural stem cell blastocysts, which was higher than
the 50% obtained from mouse fibroblasts blastocyts (Blelloch, et al., 2006).
Next, donor cells were treated with a hypomorphic allele of DNA
methyltransferase I prior to injecting them into the oocyte. Nuclei from
fibroblasts, either control fibroblasts or hypomethylated, were used as donor cells
for nuclear transfer. The hypomethylated fibroblasts had a three-fold increase in
efficiency when observing ES cell derivation (Blelloch, et al., 2006). The level of
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differentiation and the level of methylation of the donor cells have impacts on the
efficiency of the reprogramming ability of nuclear transfer (Blelloch et al., 2006).
Zebularine, a DNA methyltransferase I inhibitor, has also been used as a
treatment to maintain demethylation of cultured cells. Zebularine is a cysitidine
analogue containing a pyrimidinone ring (Yoo et al., 2004). Chang et al., (2004)
used zebularine to suppress methylation in human bladder cancer cells. One
treatment of zebularine on bladder cancer cells resulted in a hypermethylated
p16 gene (Cheng et al., 2004). A problem with this treatment is remethlyation,
which can be overcome with continuous exposure. The T24 cells (bladder
cancer cells) could be cultured overtime in zebularine because the chemical is
stable and non-toxic. Other DNA methyltransferase inhibitors cannot be used
clinically because of their instabilities and toxicities (Yoo et al., 2004). Zebularine
is very stable, non-toxic, and has a half-life of 44 hours. DNA methyltransferase
1 (DNMT1) was completely depleted when using continuous treatment with
zebularine (Cheng et al., 2004), allowing the tumor suppressor gene p16 to be
expressed. Therefore, zebularine has great potential for cancer treatment. If
p16 is expressed, it can keep the cancer cells from rapidly growing and may
result in fewer cancer cell numbers. Zebularine has a potential for clinical use as
a chemotherapeutic agent to reverse hypermethylation and reactivate regulatory
genes in cancer cells (Yoo et al., 2004). DNA methyltransferase inhibitor,
zebularine, has a potential role in cancer treatment as well as a potential role in
research for inducing certain methylation patterns in somatic cells.
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The second epigenetic modification that must be addressed is histone
acetylation. Histone acetylation and deacetylation are important modifications
involved in reprogramming and differentiating the cell nucleus. An octamer of
histones (H2A, H2B, H3, and H4) is enveloped with small fragments of DNA in an
area that is called the nucleosome (Stocum and Zupanc, 2008). The histones
have a C-terminal tail and an N-terminal, with the N-terminal tail being subject to
posttranslational modifications like acetylation (Keifer, 2007). Gametes have
histones that are acetylated as a result of the chromatin becoming highly
acetylated after fertilization (Rybouchkin et al., 2006). In bovine, there is reduced
histone acetylation at the four-cell stage, but it is then followed by an increase in
acetylation at the eight-cell stage (Yang et al., 2007). Histone acetylation is
performed by adding an acetyl group to the positively charged lysine in the
histone’s core. This will cause the DNA to become more relaxed and able to
bind the transcription activation complex in order to result in gene expression.
In order to reprogram differentiated cells, their histones must be acetylated
to allow gene expression. Deacetylation in mice embryos was observed after
nuclear transfer along with treatment of trychostatin A (TSA), a histone
deacetylase inhibitor. Blastocyst rates as well as hatching rate were higher for
the TSA treatments group when compared to the control (Rybouchkin et al.,
2006). The TSA group had an increase in cell numbers, implantation rates, in
blastocysts rates, and had an increase in full-term development to a fetus in the
treated oocytes (Rybouchkin et al., 2006). This report reveals that histone
acetylation can improve reprogramming efficiency of the donor nucleus to an ES
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cell state. A similar studied performed somatic cell nuclear transfer using
Cytochalasin B prevents the extrusion of the second polar body following
activation and Trichostatin A on pig oocytes after activation (Beebe et al., 2009).
When cytochalasin B and TSA were combined for treatment of the embryos,
there was no difference in cleavage number, however a three-fold increase the
number of blastocysts, and an increase in cell numbers in the blastocysts were
reported (Beebe et al., 2009). The cloning efficiency of cloned calves was
increased (from 2.6 to 13.4%) when a combination of TSA and 5-aza-2’deoxycytidine (DNA methyltransferase inhibitor) treatment on donor cells and
early cloned embryos was used to observe in vivo development (Wang et al.,
2011). While trichostatin A has been shown to result in increased blastocysts
rates and full-term development rates, there are other histone deacetylase
inhibitors to consider.
Huangfu et al., (2008) tested the effect of chromatin modification inhibitors
on reprogramming ability in mice cells. 5’-azacytidine (DNA methyltransferase
inhibitor), Dexamethazone (synthetic glucocorticoid), and valproic acid (VPA, a
histone deacetylase inhibitor) improved the rates of reprogramming by ten-fold,
2.6-fold, and >100-fold respectively (Huangfu et al, 2008). Mouse embryonic
fibroblasts (MEF) were induced to be pluripotent with Oct4, Sox2, Klf4, and cMyc. VPA was found to be the most efficient at assisting four-factor transduction,
resulting in a 100-fold improvement in reprogramming efficiency when compared
to the controls (Huangfu et al, 2008). Another milestone achieved in the study
was that VPA treatment was able to induce pluripotency in MEF without the
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oncogene, c-Myc, for a 50-fold increase in efficiency compared to 3 factor
infection without VPA treatment (Huangfu et al, 2008). An important aspect to
mention is that using VPA treatment on cells alone does not induce ES cell
properties (Huangfu et al., 2008).
Valproic acid was used in two more studies on inducing pluripotency.
Valproic acid, 2-propylpentanoic acid, is a short chain fatty acid that is used to
treat epilepsy and bipolar disorder in humans (Phiel et al., 2001). The highly
charged histones block binding of transcription factors to DNA. Histone
acetylation neutralizes the positive charge on DNA and generates an open
formation to cause re-expression of suppressed genes (Kuendgen et al., 2004).
Somatic cells, specifically MEF, can be reprogrammed by direct delivery of
recombinant cell-penetrating reprogramming proteins alongside treatment with
valproic acid (Zhou et al., 2009). A study on primary human fibroblasts was
performed to induce cells to become pluripotent with the use of Oct4 and Sox2
along with VPA treatment after infection. The iPS cells from the two-factor
infection had ES cell-like characteristics, but had a lower efficiency rate than the
3-factor transduction using Oct4, Sox2, and Klf4 (Huangfu et al., 2008). Both
experiments are important in verifying the ability of valproic acid to cause histone
acetylation and increase reprogramming rates when induced with pluripotency
factors. Valproic acid and zebularine have been shown to improve
reprogramming efficiencies when utilizing somatic cell nuclear transfer or direct
reprogramming. Both chemicals are stable, non-toxic, and have been used in
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human medicine. These properties make them desirable to be utilized alongside
viral transduction to improve reprogramming of somatic cells.
Gene Expression Associated with Reprogrammed Cells
Specific genes have been reported for their expression in ES cells and
pluripotent cells. Three of these genes are Oct4, Sox2, and Nanog. In order for
an embryo to develop, the cell fates must be determined at the correct time by
these essential transcription factors. For development of an embryo into a viable
blastocyst, critical molecular and regulated cellular events must take place (Ovitt
and Schöler, 1998). These three genes are important for determining the cells
that will become the inner cell mass from the cells that will become trophoblasts
in the blastocyst. Oct4, Sox2, and Nanog are expressed in the inner cell mass,
which has been described above as the source of ES cells (Evans and Kaufman,
1981) or pluripotent cells. Oct4 and Nanog promoters were found demethylated
(genes are being expressed) in human ES cells (Takahashi et al., 2007). The
same demethylation of the promoters can be found in iPS cells. However, MEF
had methylated promoters (Wernig et al., 2007). The promoters for Oct4 and
Nanog in induced pluripotent cells were discovered to have increased histone
acetylation and decreased demethylation (Takahashi and Yamanaka, 2006). In
order to test somatic cells for their ability to become pluripotent after direct
reprogramming, these genes must be observed for their expression in the
infected cells.
Oct4 is a transcription factor that regulates cell differentiation and is
required for ES cell development. Oct4 is a member of the POU transcription
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factor family, and may only be expressed by totipotent or pluripotent cells (Hattori
et al., 2004). It is also known as Oct3 or POU5F1, and it is expressed in early
embryo development (Ovitt and Schöler, 1998). Oct4 is down regulated in
trophoblast cells; however it will still be expressed in the inner cell mass of the
blastocyst. As cells differentiate, Oct4 expression will become suppressed (Ovitt
and Schöler, 1998). Oct4 was found to be a “master regulator” in the ES cells
because changing concentrations of Oct4 would change the cell’s fate (Niwa et
al., 2000). Oct4 is not expressed in trophoblasts, fibroblasts, the placenta, and
other somatic cells (Hattori et al., 2004). Oct4 has been reported to be
expressed when the trophoblast stem cells are treated with a DNA
methyltransferase inhibitor and histone deacetylase inhibitor (Hattori et al., 2004).
Alone, each inhibitor could not result in expression. However, repression of Oct4
led to differentiation into trophectoderm (Hattori et al., 2004). A noteworthy fact
was the DNA methylation percentage of ES cells compared to trophoblast stem
cells. The ES cells are 5% methylated (hypomethylated), and the trophoblast
stem cells are 74% methylated (Hattori et al., 2004). Therefore DNA methylation
is critical for regulating Oct4 expression. These findings present evidence that
Oct4 expression is needed for somatic cells to reprogram to a pluripotent state
because Oct4 is only expressed in totipotent and pluripotent cells. Oct 4 is
crucial to determine embryo cell fates. Oct4 is required for the maintenance of
pluripotency or for the prevention of differentiation of the pluripotent cells (Ovtitt
and Schöler, 1998). Niwa et al., (2000) found that a less than two-fold increase
in Oct4 expression levels causes differentiation of the embryo into primitive
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endoderm and mesoderm, providing evidence that a specific and crucial amount
of Oct4 is required for regulation of cell differentiation. DNA methylation and
histone deacetylation represses Oct4 gene expression in the trophoblast cells
(Hattori et al., 2004). Oct4 and Sox2 are critical core factors in determining
pluripotency (Stocum and Zuplanc, 2008). All pluripotent and totipotent cells of
the embryo and undifferentiated cells express Oct4 (Ovitt and Schöler, 1998).
A second gene expressed by pluripotent cells is Sox2. The Oct4
transcription factor has been shown to activate the transcription of other genes
including Sox2 (Niwa et al., 2000). A member of the SOX family, Sox2, is an
SRY-related gene (Sex Determining Region-Y) with an HMG (High Mobility
Group) DNA-binding domain (Avilion et al., 2003). Sox2 is expressed in the inner
cell mass of a blastocyst and is essential to ES cell identity. Sox2 expression
has been reported in the inner cell mass, morula, blastocyst, and on into the
neuroectoderm (Avilion et al., 2003). Sox2 is required to maintain the
undifferentiated state. When Sox2 is absent, the cells will differentiate into
trophoblast giant cells (Avilion et al., 2003). It has been reported that Sox2
regulates the multiple transcription factors, which in turn are responsible for
regulating Oct4 expression (Masui et al., 2007). Sox2 expression is stimulated
by Oct4 (Hattori et al., 2004), and they work together to regulate embryo
development and cell differentiation. However, it has also been reported that
Sox2 is necessary to regulate certain factors that affect Oct4 expression (Masui
et al., 2007). When Sox2 is down regulated, Oct4 will be down regulated as well
and will result in an up-regulation of Oct4 repressors (Masui et al., 2007). Oct4
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and Sox2 may work together to maintain pluripotency and establish early
embryonic cell fates and the first few lineages present in the embryo at the time
of pre-implantation (Aviolion et al., 2003).
The last key factor in determining embryonic cell fate is Nanog. Nanog,
named after the mythical Celtic land of the ever young, is a homeodomain protein
that is responsible for maintaining pluripotency (Chambers et al., 2003). Nanog
has a role in pluripotency of the inner cell mass and embryonic stem cells, and it
is able to maintain pluripotent cells without the help of Leukemia inhibitory factor
(LIF) (Mitsui et al., 2003). Nanog has been found in ES cells and embryonic
carcinoma cells in mice and humans (Chambers et al., 2003). Nanog expression
levels are low at the morula stage, however expression levels are high at the
blastocyst stage implying that Nanog may be the crucial factor in distinguishing
the pluripotent epiblasts (expressing Nanog) from the endoderm (Mitsui et al.,
2003). If Nanog expression is suppressed, the ES cells will differentiate into
endoderm cells (Mitsui et al., 2003). Nanog expression is regulated by
epigenetic modifications, much like Oct4. Nanog and Oct4 are essential in
maintaining pluripotent cells during early embryonic development (Hattori et al.,
2007). All three genes, Oct4, Sox2, and Nanog, are essential to maintaining and
determining pluripotent stem cells.
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CHAPTER III
EXPRESSION OF OCT4, SOX2, AND NANOG IN BOVINE ADIPOSE STEM
CELLS TREATED WITH VALPROIC ACID OR ZEBULARINE
Introduction
Stem cells are able to renew themselves constantly and are able to
differentiate into multiple lineages (Bunnell et al., 2008). Adult stem cells are
somatic cells that have similar characteristics of embryonic stem (ES) cells.
They possess multipotent capabilities, which means that the cells are able to
differentiate into multiple cells from the same tissue origin (Pittenger et al., 1999).
Adult stem cells can be found numerous places in the adult body including bone
marrow, blood, and adipose tissue. Characterization of adipose-derived stem
cells in humans (Zuk et al.,2002; Gimble and Guilak, 2003; Bunnel et al., 2008)
and in bovine (Williams et al., 2008; Picou, 2009) has been previously reported.
Additionally, bovine adult stem (bADS) cells have been found to express
pluripotency genes associated with ES cells (Coley, 2010). Adipose stem cells
are multipotent, can be isolated fairly easy from people of all ages, and are able
to proliferate extensively (Pittenger et al., 1999; Sun et al., 2009).
The aforementioned capabilities of adipose-derived stem (ADS) cells
make them a desirable source for reprogramming experiments. The goal of
reprogramming experiments is to transform somatic cells from a differentiated
state to a pluripotent or totipotent state. If somatic cells contained pluripotent
qualities, they could potentially differentiate into cells of the three germ layers
that generate an embryo. Previously, somatic cells were thought to have
irreversible cell nuclei that could not reprogram (Hochedlinger and Jaenisch,
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2006); however, this statement has been discovered to be false. There are
several ways to reprogram somatic cells: exposure to ES cell extracts
(Hochedlinger and Jaenisch, 2006), fusion with ES cells (Cowan et al., 2005),
nuclear transfer (Briggs and King, 1952; Gurdon et al., 1958; Illmensee and
Hoppe, 1981; Wilmut et al., 1997), and direct reprogramming with viral
transduction (Takahashi and Yamanaka, 2006, 2007; Wernig et al., 2007; Yu et
al., 2007; Lowry et al., 2008; Carey et al., 2009). The first mammal produced by
completely reprogramming a somatic cell utilizing nuclear transfer was Dolly
(Wilmut et al., 1997). Until recently, nuclear transfer was the most popular
procedure; however, success was reported reprogramming using viral
transduction (Takahashi et al., 2006).
When somatic cells are reprogrammed, there are certain epigenetic
changes or modifications that must occur in order to successfully reprogram the
nucleus. The low number of viable embryos produced in somatic cell nuclear
transfer is probably due to incomplete nuclear reprogramming (Li et al., 2003).
These changes are adjustments to the gene function without any change to the
DNA sequence (Kiefer, 2007). Epigenetic modifications will change the
chromatin configuration and are a result of DNA methylation and histone
acetylation. Somatic cells can be exposed to small molecules that may be able
to reduce the chances of having incomplete chromatin modification (Stocum and
Zupanc, 2008). Two epigenetic modifying factors are a DNA methyltranferase I
inhibitor and a histone deacetylase inhibitor. DNA methyltransferase I inhibitor,
zebularine (Zeb), has been shown to produce higher reprogramming efficiencies
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when used in nuclear transfer (Blelloch et al., 2006) and in cancer cell culture
(Cheng et al., 2004). The DNA methyltransferase I inhibitor would result in DNA
demethylation, allowing the transcription factors to bind the DNA. This would
result in gene expression. Similar results can be achieved with a histone
deacetylase inhibitor. The histone deacetylase inhibitor would cause the
histones to become acetylated and result in the DNA being able to bind the
transcription factors that can cause gene expression. Trichostatin A and valproic
acid (VPA) are a couple of histone deacetylase inhibitors. The use of trichostatin
A has led to increased blastocysts rates and full-term development rates with
nuclear transfer on pig oocytes (Beebe et al., 2009). VPA was able to improve
reprogramming rates in induced pluripotent stem cells in mice (Huangfu et al,
2008; Zhou et al., 2009) and in humans (Huangfu et al., 2008). The epigenetic
modifications can stimulate the cells to reprogram more efficiently by increasing
the pluripotency-associated genes. VPA and Zeb have both been observed and
shown to improve reprogramming efficiencies in somatic cell nuclear transfer
(Blelloch et al., 2006; Beebe et al., 2009), cell culture (Cheng et al., 2004), and
direct reprogramming (Huangfu et al, 2008; Zhou et al., 2009). Each chemical
has been reported to be stable, non-toxic, and previously has been used in
human medicine.
Three genes essential to maintaining and determining pluripotent cells are
Oct4, Sox2, and Nanog. ES cells and pluripotent cells have high levels Oct4,
Sox2, and Nanog. These three genes have been reported for their presence in
adult stem cells, specifically bovine ADS cells (Coley, 2010). In order for an
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embryo to develop, the cell fates must be determined at the correct time by these
essential transcription factors. Oct4, Sox2, and Nanog have major roles in
determining the cells that will become the inner cell mass, the source of ES cells
or pluripotent cells (Evans and Kaufman, 1981). Oct4, a transcription factor, is a
member of the POU transcription factor family (Hattori et al., 2004). Oct4
regulates cell differentiation and may only be expressed by totipotent or
pluripotent cells. Sox2 is an SRY (Sex Determining Region-Y)-related gene with
a HMG (High Mobility Group) DNA-binding domain (Avilion et al., 2003). Finally,
Nanog is a homeodomain protein that is responsible for maintaining pluripotency
(Chambers et al., 2003). All three genes, Oct4, Sox2, and Nanog, are essential
to maintaining and determining pluripotent stem cells. These genes are
important when considering epigenetic modifications. The levels of gene
expression of the three genes of interest may be able to increase after treatment
with the small molecule inhibitors in certain adult stem cells that previously
expressed the pluripotency-associated genes.
In this study, three lines (representing three separate cows) of bovine ADS
cells were isolated from the stromal fraction of adipose tissue and expanded
through 3 passages. The cells were treated with VPA or Zeb to observe the
changes in transcript levels of Oct4, Sox2, Nanog, and Poly A. The cells were
treated for a period of 5, 7,10, or 14 days. Quantitative RT-PCR was performed
on the cDNA, and the data was analyzed for statistical analysis. We
hypothesized that treatment of the bovine DS cells with the modifiers would result
in an increase in pluripotency-associated genes, Oct4, Sox2, and Nanog.
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Materials and Methods
Stem Cell Isolation and Culture
Bovine adipose-derived stem (bADS) cells were isolated from adipose
tissue collected from a local abattoir. Three adipose tissues were collected from
the brisket of an adult cow and transported to the lab in Dubelcco’s phosphate
buffered saline (DPBS) with Ca2+ and Mg2+ + 2% penicillin/streptomycin (P/S) +
2% Fungizone (Gibco, 15290-018) on ice. The samples were washed twice and
minced. The wash was aspirated off of the minced tissues, and the tissues were
transferred to 150 mL Erlenmeyer flasks containing a collagenase solution of
DPBS with Ca2+ and Mg2+, One percent of bovine serum albumin (BSA), 0.25%
collagenase type I (Gibco, 17100-017), 1% P/S, and 1% Fungizone. The
Erlenmeyer flasks were placed in a continuous shaking incubator at 200 rpm at
37 °C for 2 hours. After incubation, the tissues and solutions were centrifuged
twice at 1200 rpm for 5 minutes and shaken vigorously between centrifugations.
The adipose tissues were discarded from the tube, and the liquids were
transferred into a fat filter syringe system with a double filter consisting of 80 μm
and 120 μm nylon filters. After a series of four centrifugations, aspirations and
resuspensions, the cell pellets were finally resuspended in 1 mL of culture
medium containing DMEM (high glucose) + 10% fetal bovine serum (FBS) + 1%
Penicillin/Streptomycin (P/S). The resuspended cells were plated in individual
12.5 cm2 flasks. After the cells were cultured for 24 hours, a primary wash of 2
mL of DPBS with Ca2+ and Mg2+ was used to rinse the flasks. After aspiration of
the DPBS wash, 3 mL of fresh culture medium was added.
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The adherent bADS cells were maintained by trypsin passage. When
cells reached 90% confluency, the old medium was aspirated and a wash of
DPBS (without Ca2+ and Mg2+) was be added and aspirated. Trypsin (0.25%
EDTA) was added to the flasks in order to disaggregate the cells. The cells were
transferred to 15 mL tubes and centrifuged at 1200 rpm for 5 minutes to form cell
pellets. The pellets were resuspended in 1 mL of culture medium and used to
calculate the number of cells present by using a hemocytometer. The bADS
cells were re-seeded at 7.0 x 106 in 25 cm2 flasks.
Cell Cryopreservation
Trypsinizing and centrifuging the cells (as above) started the
cryopreservation protocol for the cells. Once cells were pelleted, Calf serum
(C/S) + 10% Dimethyl Sulfoxide (DMSO) (Sigma, No. D2650) was be used to
resuspend the pellet. The resuspended cells were divided into cryovials and
cooled at 1ºC/minute until reaching -80°C in a freezer. After 24 hours, the cells
could be moved form the -80ºC to a liquid nitrogen tank. When thawing the cells,
cells were allowed to sit a room temperature for 30 seconds before being placed
in a 37ºC water bath.
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Treatment with VPA or Zeb
Three different cell lines of bADS cells, representing three different
animals, were exposed to 5 mM VPA, a DNA methyltranferase inhibitor, or 100
µM Zeb (Sigma Z4775-5MG), a histone deacetylase inhibitor. On Day one,
50,000 cells were plated in each well (18 in total) of a 24 well tissue culture dish.
After 24 hours, the bADS cells were divided into a control group (receiving
standard culture medium - DMEM + 10% calf serum + 1%
Penicillin/Streptomycin), a group treated with VPA (culture medium + 5 mM
VPA), and a group treated with Zeb (culture medium + 100 µM zebularine). The
media was changed every three days. mRNA was isolated and converted to
cDNA on days 5, 7, 10, or 14. The cDNA was then used in quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR) to observe expression
levels.
mRNA Isolation using Dynabeads® Oligo (dT) 25
bADS cells were used from culture for mRNA isolation using Dynabeads®
mRNA DIRECT™ Kit (Invitrogen Dynal AS, Oslo, Norway). The medium was
aspirated and trypsin was added to disaggregate the cells. The cells were
moved to a 15 mL conical tube along with DMEM (high glucose) to inactivate the
trypsin. The tube was centrifuged at 1200 rpm for 5 minutes to form a cell pellet.
The cell pellet was resuspended in 1 mL of DPBS and transferred to a 1.5 mL
microcentrifuge tube. After another centrifugation, the supernatant was removed
and lysis/binding buffer was added. The cells were vortexed for 10 seconds,
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stripped with a 21-gauge needle to damage the cell membrane, and centrifuged
at 12000g for 15 seconds. After the cells were incubated for 10 minutes at room
temperature, pre-washed dynabeads (washed with lysis/binding buffer twice)
were added. The dynabeads and cells were placed in the rotator for 10 minutes
at room temperature. The tube was then placed in a magnetic separator and the
supernatant was removed. A series of washes was performed before eluting the
RNA with 15 µL DEPC-treated water. The water and RNA were placed at 70 °C
for 2 minutes. After placing the sample into the magnetic sample, the RNA was
collected by removing the supernatant.
Converting mRNA to cDNA using iSCRIPT™ kit
The 15 µL of DEPC-treated water containing the mRNA was transferred to
a PCR tube. 4 µL of iScript reaction mix and 1 µL of reverse transcriptase from
the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) were added to the tube. The PCR tube was placed into a Thermocyler for
5 minute at 25 °C, 30 minutes at 42 °C, and 5 minutes at 85 °C. After the cycler
was finished, the cDNA was kept at -80 °C.
Quantitative Reverse Transcriptase Polymerase Chain Reaction
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
was performed using SsoFastTM EvaGreen® Supermix (Bio-Rad) on a Roche
LightCylcer® 480 II Real-Time PCR System (Roche Applied Science,
Indianapolis, IN, USA) to test for changes in Oct4, Sox2, and Nanog using Poly A
(Poly Adenylate Polymerase or PAP) as an internal reference gene. 1 µL
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forward primer (10 mM), 1 µL reverse primer (10 mM), 6 µL nuclease free water,
and 2 µL of cDNA (from sample) were added to 10 µL of SsoFast. The primers
for Oct4, Sox2, Nanog, and Poly A (Table 3.1) were purchased from Invitrogen
(CA, USA). A total of 20 µL was added to each well in a 96 well PCR plate.
Each plate contained samples (replicated in doubles), positive
controls/calibrators (replicated in triplicates), and negative controls (containing no
templates). The reaction consisted of enzyme activation (30 seconds at 95 °C)
and 40 cycles of denaturation (5 seconds at 95 °C) and annealing/extension (20
seconds at 55 °C). A final melt curve analysis with a final holding temperature of
40°C was performed to conclude the PCR.
The quantitative data was calculated using relative quantification - ∆∆CT
method. The relative quantification method calculates a numerical value for the
cDNA samples by comparing a ratio between expressions of two genes (for
example Oct4 to PolyA). The basic relative quantification method performs
analysis by using Fit points method for Cp and by using ∆∆CT Method. The
∆∆CT method calculates an n-fold difference by dividing the efficiency of the
target gene ∆CTT by the efficiency of the reference gene ∆CTR (assuming an
efficiency of 2). A ∆CT for the target gene was calculated by subtracting the CT
value for the target gene from the CT value for the calibrator. Last, a ∆CR for the
reference gene was calculated by subtracting the CT value for the sample from
the CT value of the reference. A calibrator can be utilized in the PCR program to
further normalize the data. The calibrator used was a combination of four lines of
bADS cells that were untreated from passages 2-6, and used to give a consistent
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ratio of target gene to reference gene expression for each run.
Table 3.1 Sequences and resulting amplicon lengths for primers used in qRTPCR.
Gene

Amplicon
Length

Sox2

Primer Sequence
Sense – GGTTCTCTTTGGAAAGGTGTTC
Antisense - ACACTCGGACCACGTCTTTC
Sense – AGGACTGAGAGAAAGAAGAAGAG
Antisense – AAGAAAGAGGCAAACTGGAATC

Nanog

Sense – AATTCCCAGCAGCAAATCAC
Antisense - CCCTTCCCTCAAATTGACAC

164

PolyA

Sense – AAGCAACTCCATCAACTACTG
Antisense - ACGGACTGGTCTTCATAGC

169

Oct4

223
215

Statistical Analysis
Statistical analysis was performed on the data using SAS®. Normalized
ratios were log transformed prior to analysis by ANOVA to correct for lack of
normality. A one-way ANOVA was completed to test the statistical significance,
utilizing a P value of 0.05, among the control and treatment groups for each day.
Furthermore, a pair wise comparison was conducted to test for significant
differences between the VPA and Zeb treatments.
Table 3.2 F values and corresponding probabilities from single factor ANOVA for
transcript levels for Oct 4, Sox2 and Nanog from cells after five days of
treatment.
ANOVA

F Value

Pr > F

Oct4

20.99362

0.001955

Sox2

4.778699

0.057364

Nanog

9.794859

0.01289
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Gene Expression Ratio

Table 3.3 Log transformations of mean transcript levels for Oct4, Sox2 and
Nanog in cells treated for 5,7,10 or 14 days. Values marked with asterisks (*) are
different (P<.05) than controls for the corresponding gene after that duration of
treatment.
Days of
Exposure

Treatment

Oct4

Sox2

Nanog

5

Control

1.278

0.813

0.981

5

VPA

3.007*

2.792

2.639*

5

Zeb

2.858*

3.084

2.499*

7

Control

1.784

1.244

1.735

7

VPA

2.215

0.565

2.007

7

Zeb

2.499

3.330

2.147

10

Control

2.118

1.964

2.355

10

VPA

2.822

3.310

3.510

10

Zeb

2.228

2.013

2.456

14

Control

1.355

1.816

2.001

14

VPA

1.629

1.669

2.840

14

Zeb

1.259

1.208

1.646
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Figure 3.1. Log transformations of mean relative transcript levels (+/- SEM) for
Oct4, Sox2 and Nanog in cells treated for 5,7,10 or 14 days.
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Results
Significant differences in gene expression were found on Day 5 between
the control and treatment groups for transcript levels of Oct4 and Nanog (Table
3.3); however, the treatments did not produce differences in gene expression
levels of Oct4, Sox2, and Nanog on days 7, 10, or 14. Table 3.3 presents the
ratios from this experiment with the gene expression for each treatment group
over the four days.
Discussion
Adult stem cells, such as ADS cells, share unique characteristics with ES
cells. These cells have been shown to possess multipotent capabilities and
proliferate extensively while still possessing the ability to differentiate into various
cell types (Pittenger et al., 1999). ADS cells are desirable in research due to
their unique characteristics: are multipotent, can be isolated from mammals of all
ages, and ease of isolation of the stem cells (Sun et al., 2009). There are
several potential applications for use of ADS cells in research (Gimble and
Guilak, 2003). The cells can be used to repair injured tissues in patients with
irreparable injuries or diseases (Takahashi and Yamanaka, 2006). ADS cells
may be advantageous when performing direct reprogramming experiments for
producing pluripotent cells similar to ES cells. A third application is to use the
ADS cells to better understand cellular functions such as DNA methylation or
histone acetylation (Stocum and Zupanc, 2008). DNA methylation and histone
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acetylation are two epigenetic modifications that must occur in the cells to
successfully reprogram to a pluripotent state.
In the present experiment, bADS were treated with VPA or Zeb for a
period of 5, 7, 10, or 14 days to observe the changes in Oct4, Sox2, and Nanog.
The bADS cells were exposed to small molecules that may be able to reduce the
chances of having incomplete epigenetic modification (Stocum and Zupanc,
2008). Zeb, a DNA methyltransferase I inhibitor, has been revealed to produce
higher reprogramming efficiencies when used in nuclear transfer (Blelloch et al.,
2006) and in cancer cell culture (Cheng et al., 2004). VPA, a histone
deacetylase inhibitor, improved reprogramming rates in induced pluripotent stem
cells in mice (Huangfu et al, 2008; Zhou et al., 2009) and in humans (Huangfu et
al., 2008). Observation of Oct4, Sox2, and Nanog is essential because they play
key roles in determining the pluripotent cells of the blastocyst (Evans and
Kaufman, 1981), and they have been found to be present in bovine adiposederived adult stem cells (Coley, 2010). These genes are also important when
considering epigenetic modifications because the levels of gene expression may
increase after treatment with the inhibitors.
When cells were treated for 5 days, Oct4 and Nanog expression levels
were increased significantly (P<0.05) between the control and treatment groups
while Sox2 was not different across treatment groups. The pair wise comparison
revealed VPA and Zeb treated groups not significantly different from each other.
Treatment for 7,10 or 14 days did not result in any difference in transcript levels
between the treatment groups and control for any of the genes analyzed. This is
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likely due to the low sample size of four cell lines. The experiment would have
greater power with an increased amount of cell lines. An increase in power may
reveal some statistical differences between treatments. Also, the values of gene
expression ratios had large variations among each day, treatment, and cell line.
For this reason, the data had to be normalized using the log transformation.
VPA and Zeb treatment for 5 days may have produced a partial
reprogramming. VPA treatment led to higher Oct4, Sox2, and Nanog gene
expression ratios. As shown in Table 3.3, the levels for the pluripotencyassociated genes were elevated on days 5 and 10, with increased and
decreased values on days 7 and 14. While this study did not find a difference in
VPA treatment overall, Table 3.3 presents the ability of VPA to increase levels of
gene expression for each days of exposure. VPA has been shown to cause
histone acetylation and increase reprogramming rates when induced with
pluripotency factors (Huangfu et al., 2008; Zhou et al., 2009). VPA has also
been reported to be the most efficient at assisting four-factor transduction by
producing a 100-fold improvement on reprogramming efficiencies in MEF
(Huangfu et al, 2008).
The gene expression ratio levels for Oct4, Sox2, and Nanog were also
increased with Zeb treatment. Notably, the values for the three genes were
lower than those produced by VPA treatment (Table 3.3). Zeb treatment overall
did not have a predictable pattern of influencing gene expression ratios. In
previous studies, Zeb was able to suppress methylation in human bladder cells
(Chang et al., 2004), and it has been reported that hypomethylation in fibroblasts
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led to a three-fold increase in efficiency when observing ES cell derivation
(Blelloch, et al., 2006).
In our study, bovine ADS cells treated for 5 days exhibited an increase in
Oct4 and Nanog expression levels compared with the control and treatment
(VPA and Zeb) groups. Sox2 was discovered to be not significant at the P<0.05
level (P=0.06). Notably, VPA and Zeb treated groups were not different from
each other in their ability to impact gene expression. VPA and Zeb treatments
did not produce statistical differences in gene expressions of Oct4, Sox2, and
Nanog on days 7, 10,and 14. While VPA led to the highest increase of Oct4,
Sox2, and Nanog, both treatments may have produced a partial reprogramming.
This partial reprogramming may result in the bADS cells reaching complete
pluripotency when combined with a reprogramming technique. Although further
studies must be performed in order to validate this claim, this study showed that
treatment of bADS with VPA or Zeb could increase the levels of pluripotencyassociated genes.
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CHAPTER IV
LENTIVIRAL TRANSDUCTION OF BOVINE ADIPOSE STEM CELLS
TREATED WITH VALPROIC ACID OR ZEBULARINE

Introduction
Somatic cells have been examined for their ability to reprogram to a
totipotent or pluripotent state. In the past, somatic cells were thought to have
irreversible cell nuclei that could not be reprogrammed (Hochedlinger and
Jaenisch, 2006), but that statement has been proven false. Differentiated cells
have been successfully reprogrammed to a totipotent state by nuclear transfer
(Briggs and King, 1952; Gurdon et al., 1958; Illmensee and Hoppe, 1981; Wilmut
et al., 1997), and to a pluripotent state by direct reprogramming with viral vectors
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Wernig et al., 2007; Yu
et al., 2007; Lowry et al., 2008; Carey et al., 2009). Despite the success with
reprogramming somatic cells, the reprogramming rates achieved with direct
reprogramming are very low at less than 0.03% (Stocum and Zupanc, 2008). To
improve the reprogramming rates, epigenetic modifications during development
must be considered.
Stem cells are able to differentiate into multiple lineages and constantly
renew themselves (Bunnell et al., 2008). Two forms of stem cells are adult stem
cells and embryonic stem cells. Adult stem cells have similar characteristics of
embryonic stem (ES) cells; particularly they possess multipotent capabilities,
which enable them to differentiate into multiple cells from the same tissue origin
(Pittenger et al., 1999). A unique characteristic of ES cells is their ability to
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renewal themselves indefinitely in culture (Odorico et al., 2001; Stocum and
Zupanc, 2008). The adult stem cells are also able to renew themselves while still
maintaining the ability to differentiate into specific cell types of a certain origin
(Pittenger et al., 1999). A few sources for adult stem cells in the adult body are
bone marrow, blood, and adipose tissue. Characterization of adipose-derived
stem cells in humans (Zuk et al.,2002; Gimble and Guilak, 2003; Bunnel et al.,
2008) and in bovine (Williams et al., 2008; Picou, 2009) has been previously
reported. Bovine adipose-derived stem (ADS) cells have been reported to
express specific pluripotency-associated genes, Oct4, Sox2, and Nanog (Coley,
2010). The bovine ADS cells were found to differentiate into chondrocytes,
osteoblasts, and adipocytes (Picou, 2009). These characteristics make bovine
ADS cells an ideal source for stem cell research.
A popular focus in today’s human medicine is induced pluripotent stem
(iPS) cells. Somatic cells, previously not pluripotent, can be reprogrammed to
become pluripotent (Takahashi et al., 2007). Reprogramming the somatic cells
can be done by viral vector transduction of the cells to produce cells that have
the ability to differentiate into all three germ layers. The viral vector transduction
system consists of three plasmids, containing the pluripotency-associated genes
that will assemble a virus inside 293T cells. Once the viruses are assembled, the
viruses will lyse the 293T cells, and the viral particles can be collected along with
the culture medium. The viral particles can then be used to treat target cells to
cause endogenous expression of the pluripotency-associated genes, Oct4, Sox2,
and Nanog, to produce iPS cells. The pluripotency-associated genes where
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selected from a pool of 24 transcription factors ability to produce iPS cells from
use embryonic fibroblasts. The iPS cells were described as morphologically
similar to ES cells, exhibiting a round shape, large nucleoli, and little cytoplasm
(Takahashi and Yamanaka, 2006). It was reported that Oct4, Sox2, Klf4, and cMyc were essential to the production of iPS cells, and are referred to as the
“Yamanaka four factors” (Takahashi and Yamanaka, 2006). Somatic cells may
be observed to have similar morphology to ES cells once transformed into iPS
cells; however, morphology alone cannot determine pluripotency. Quantitative
RT-PCR is another means to test the cells ability to become pluripotent by
examining the presence and levels of expression of ES cell markers. iPS cells
have been produced using a transduction system containing Oct4, Sox2, Klf4,
and c-Myc in human dermal fibroblasts (Takahashi et al., 2007; Lowry et al.,
2008), mouse embryonic fibroblasts (Takahashi and Yamanaka, 2006; Wernig et
al., 2007), and mouse tail-tip fibroblasts (Wernig et al., 2007).
The transduction system consisted of a plasmid for each transcription
factor, Oct4, Sox2, Klf4, and c-Myc. These four plasmids provide a problem with
multiple proviral integrations, which can lead to insertional mutagenesis (Carey et
al., 2009). In order to avoid insertional mutagenesis, a single plasmid was
constructed to contain all four factors (Oct4, Sox2, Klf4, and c-Myc) that were
separated by three 2A peptides (Carey et al, 2009). Fibroblasts are the most
common cell type used in reprogramming experiments with viral vector
transduction. An alternative to using fibroblasts is the use of adipose stem cells
(Sun et al., 2009). Human adipose stem cells were able to reprogram when
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transduced with a lentivirus containing Oct4, Sox2, Klf4, and c-Myc (Takahashi et
al., 2007; Lowry et al., 2008; Sun et al., 2009). Somatic cells in mice (Takahashi
and Yamanaka, 2006; Wernig et al., 2007; Carey et al, 2009), humans
(Takahashi et al., 2007; Lowry et al., 2008; Sun et al., 2009), and pigs (Ezashi et
al., 2009; West et al., 2009) have been reported to possess pluripotent
capabilities when induced using a transduction system.
While iPS cells have many advantages, they also have a few negative
aspects. The viral transduction method is a slow and inefficient process because
reprogramming somatic cells results in a low reprogramming rate (Huangfu et al.,
2008). A second barrier with the viral system is limitations on utilization of the
iPS cells in reparative medicine because of the integration of known oncogenes,
c-Myc and Klf4 (Wernig et al., 2007; Huangfu et al., 2008). There has been very
little research conducted on iPS cells and the medizmal affects they will have
overtime. In order to correct these problems, iPS cells were produced using a
histone deacetylase inhibitor (Huangfu et al., 2008; Zhou et al., 2009). The use
of the histone deacetylase inhibitor allowed for c-Myc to be removed from the
vector to decrease the possibility of integrating this known oncogene and
enhance the chances of using iPS cells in reparative studies.
The histone deacetylase inhibitor has another role in nuclear
reprogramming. When somatic cells are triggered to reprogram, there are
certain epigenetic changes that must occur in order to successfully reprogram
the nucleus to a less differentiated state. These epigenetic modifications change
the chromatin configuration without changing the DNA sequence. It has been
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shown that somatic cells can be exposed to small epigenetic modifying factors in
order to facilitate these epigenetic modifications required for reprogramming
towards pluripotency. Two of these epigenetic modifying factors are zebularine
(Zeb), a DNA methyltranferase inhibitor, and valproic acid (VPA), a histone
deacetylase inhibitor. Valproic acid and zebularine have been shown to improve
reprogramming efficiencies when utilizing somatic cell nuclear transfer or direct
reprogramming (Cheng et al., 2004; Huangfu et al., 2008; Zhou et al., 2009).
Both chemicals are stable, non-toxic, and have been used in human medicine.
These properties make them desirable to be utilized alongside viral transduction
to improve reprogramming of somatic cells. By enhancing Oc4, Nanog and Sox2
expression with these epigenetic modifiers, somatic cells may be reprogrammed
more effectively.
As previously reported in Chapter III, bovine ADS cell exposure to VPA
and Zeb resulted in significant differences in transcript levels of Oct4 and Nanog
between treatment and control groups. VPA and Zeb treatment increased the
levels of the pluripotency-associated genes. For this reason, a partial
reprogramming may have taken place, and complete pluripotency may be
achieved when combined with viral transduction.
In this experiment, three bADS cell lines (from three separate cows) at
passage 3 were treated with VPA or Zeb for 5 days before being exposed to a
lentivirus containing Oct4, Sox2, Klf4, and c-Myc for 24 hours. The cells were
observed for changes in cell morphology and transcript levels of Oct4, Sox2, or
Nanog.
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Materials and Methods
Stem Cell Isolation and Culture
Bovine adipose-derived stem (bADS) cells were isolated from adipose
tissue collected from a local abattoir. The adipose tissues were taken from the
brisket of an adult cow and transported to the lab in Dubelcco’s phosphate
buffered saline (DPBS) with Ca2+ and Mg2+ + 2% penicillin/streptomycin (P/S) +
2% Fungizone (Gibco, 15290-018) on ice. The adipose tissue samples were
washed twice and minced. The wash was aspirated off of the minced tissues,
and the tissues were transferred to 150 mL Erlenmeyer flasks containing a
collagenase solution of DPBS with Ca2+ and Mg2+, One percent of bovine serum
albumin (BSA), 0.25% collagenase type I (Gibco, 17100-017), 1% P/S, and 1%
Fungizone. The Erlenmeyer flasks were placed in a continuous shaking
incubator at 200 rpm at 37 °C for 2 hours. After incubation, the tissues and
solutions were centrifuged twice at 1200 rpm for 5 minutes and shaken
vigorously between centrifugations. The adipose tissue samples were decanted,
and the supernatants were transferred into a fat filter syringe system with a
double filter consisting of 80 μm and 120 μm nylon filters. After a series of four
centrifugations, aspirations and resuspensions, the cell pellets were resuspended
in 1 mL of culture medium containing DMEM (high glucose) + 10% fetal bovine
serum (FBS) + 1% P/S. The resuspended cells were plated in individual 12.5
cm2 flasks. After the cells were cultured for 24 hours, a primary wash of 2 mL of
DPBS with Ca2+ and Mg2+ was used to rinse the flasks. After aspiration of the
DPBS wash, 3 mL of fresh culture medium was added.
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The adherent bADS cells were maintained by trypsin passage. When
cells reached 90% confluency, the old medium was aspirated and cells washed
with DPBS (without Ca2+ and Mg2+). Trypsin (0.25% EDTA) was added to the
flasks in order to disaggregate cells. The recovered cells were transferred to 15
mL tubes and centrifuged at 1200 rpm for 5 minutes to form cell pellets. The
pellets were resuspended in 1 mL of culture medium and used to calculate the
number of cells present using a hemocytometer. The bADS cells were reseeded at 7.0 x 106 in 25 cm2 flasks in standard culture medium.
Cell Cryopreservation
Following trypsinization and centrifugation, calf serum (C/S) + 10%
Dimethyl Sulfoxide (DMSO) (Sigma, No. D2650) was be used to resuspend the
pellet. The resuspended cells were divided into cryovials and cooled at
1ºC/minute until finally reaching -80°C. After 24 hours, the cells were transferred
form -80ºC to a liquid nitrogen tank. For thawing, cells were allowed to incubate
at room temperature for 30 seconds before being placed in a 37ºC water bath.
Treatment with VPA or Zeb
Three different cell lines of bADS cells, representing three different
animals, were exposed to 5 mM VPA, a DNA methyltranferase inhibitor, or 100
µM Zeb (Sigma Z4775-5MG), a histone deacetylase inhibitor. On Day 1, 50,000
cells were plated in each well (18 in total) of a 24 well tissue culture dish. After
24 hours, the bADS cells were divided into six treatment groups. The six
treatment groups were a control group (receiving standard culture medium 57

DMEM + 10% calf serum + 1% Penicillin/Streptomycin), a VPA treated group
(culture medium + 5 mM VPA), a VPA and lentivirus treated group, a Zeb treated
group (culture medium + 100 µM zebularine), a Zeb and lentivirus treated group,
and a group treated with only with the lentivirus.
Producing the Lentiviral Particles
First, 700,000 293T (HEK) cells were plated in each 60mm dish in 5 mL of
medium (High-glucose DMEM with 10% FBS). The next day, 2.5 L of OSKM, 3
L of PAX2, 5.2 L of MD2m and 9.3 L of OPTI-MEM were combined.
Combining 6 L Fugene with 74 L OPTI-MEM made the master mix of Fugene
6 transfection reagent. Then the mixture of plasmids and Fugene was incubated
for 5 min at room temperature. 80 L of Fugene master mix was added to a
polypropylene tube, and incubated at room temperature for 20 min. The 293T
cells need to be at 50-80% confluency. Add the DNA:FUGENE mix drop wise
to the cells. Then the 293T cells were incubated at 37C, 5% CO2 for 12-15
hours. The next morning, the medium will be changed to remove the transfection
reagent and replaced with 5mL of DMEM, 10% FBS, and 1%
penicillin/streptomycin. Over the next two days, medium harvested will be
collected and stored in a polpropylene storage tube at 4C. The solution was
centrifuged at 1,250 rpm for 5 minutes to pellet any 293T cells that may have
been collected.
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Infecting Target Cells with Lentiviral Particles
Target cells had their medium changed to fresh culture medium after 5
days of treatment, and lentiviral particles were added. For each well to be
infected in the 24 well dish, 57L of the viral particles were added. Cells were
incubated for 24 hours at 37C, 5% CO2 before changing to fresh culture
medium. After 3-4 days from initial infection, the cells were moved to a BD
MatrigelTM (hESC-quaified Matrix) coated dish along with embryonic stem cell
medium. The ES cell medium contained High-glucose Knockout DMEM, 15%
ES cell-qualified fetal bovine serum (FBS), 2mM GlutaMax-I, 1 mM non-essential
amino acids, 1000 U/mL Recombinant Mouse Leukemia Inhibitory Factor (LIF),
1M -Mercaotoethanol, and 1% Penicillin/Streptomycin. The media was
changed every two days. Cells were passaged one to two times when colonies
were observed. Messenger RNA was isolated after establishing colonies after
passaging and converted to cDNA. The cDNA was then used in quantitative
reverse transcriptase polymerase chain reaction (qRT-PCR) to observe
expression levels.
mRNA Isolation using Dynabeads® Oligo (dT) 25
Cultured bADS cells were utilized for mRNA isolation using a Dynabeads®
mRNA DIRECT™ Kit (Invitrogen Dynal AS, Oslo, Norway). The medium was
aspirated and trypsin was added to disaggregate the cells. The cells were
moved to a 15 mL conical tube in DMEM (high glucose) to inactivate the trypsin.
The tube was centrifuged at 1200 rpm for 5 minutes, then the cell pellet was
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resuspended in 1 mL of DPBS and transferred to a 1.5 mL microcentrifuge tube.
After another centrifugation, the supernatant was removed and lysis/binding
buffer was added. The cells were vortexed for 10 seconds, stripped with a 21gauge needle, and centrifuged at 12000g for 15 seconds. After the cells were
incubated for 10 minutes at room temperature, pre-washed dynabeads (washed
with lysis/binding buffer twice) were added. The dynabeads and cells were
placed in the rotator for 10 minutes at room temperature. The tube was then
placed in a magnetic separator and the supernatant was removed. A series of
washes was performed before eluting the RNA with 15 µL DEPC-treated water.
The water and RNA were placed at 70 °C for 2 minutes. After placing the sample
into the magnetic sample, the RNA was collected by removing the supernatant.
Converting mRNA to cDNA using iSCRIPT™ kit
The 15 µL of DEPC-treated water containing the mRNA was transferred to
a PCR tube. Then, 4 µL of iScript reaction mix and 1 µL of reverse transcriptase
from the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) were added to the tube. The PCR tube was placed into a Thermocyler for
5 minutes at 25 °C, 30 minutes at 42 °C, and 5 minutes at 85 °C. After the cycler
was finished, the cDNA was kept at -80 °C.
Quantitative Reverse Transcriptase Polymerase Chain Reaction
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
was performed using SsoFastTM EvaGreen® Supermix (Bio-Rad) on a Roche
LightCylcer® 480 II Real-Time PCR System (Roche Applied Science,
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Indianapolis, IN, USA) to test for changes in Oct4, Sox2, and Nanog using Poly A
(polyadenylate polymerase or PAP) as an internal reference gene. Next, 1 µL
forward primer (10 mM), 1 µL reverse primer (10 mM), 6 µL nuclease free water,
and 2 µL of cDNA (from sample) were added to 10 µL of SsoFast. The primers
for Oct4, Sox2, Nanog, and Poly A (Table 3.1) were purchased from Invitrogen
(CA, USA). A total of 20 µL was added to each well in a 96 well PCR plate.
Each plate contained samples (replicated in doubles), positive
controls/calibrators (replicated in triplicates), and negative controls (containing no
templates). The reaction consisted of enzyme activation (30 seconds at 95 °C)
and 40 cycles of denaturation (5 seconds at 95 °C) and annealing/extension (20
seconds at 55 °C). A final melt curve analysis with a final holding temperature of
40°C was performed to conclude the PCR.
The quantitative data was calculated using relative quantification - ∆∆CT
method. The relative quantification method calculates a numerical value for the
cDNA samples by comparing a ratio between expressions of two genes (for
example Oct4 to PolyA). The basic relative quantification method performs
analysis by using Fit points method for Cp and by using ∆∆CT Method. The
∆∆CT method calculates an n-fold difference by dividing the efficiency of the
target gene ∆CTT by the efficiency of the reference gene ∆CTR (assuming an
efficiency of 2). A ∆CT for the target gene was calculated by subtracting the CT
value for the target gene from the CT value for the calibrator. Last, a ∆CR for the
reference gene was calculated by subtracting the CT value for the sample from
the CT value of the reference. A calibrator was utilized in the PCR program to
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further normalize the data. The calibrator used was a combination of four lines of
bADS cells that were untreated from passages 2-6, and used to give a consistent
ratio of target gene to reference gene expression for each run.

Table 4.1 Sequences and resulting amplicon lengths for primers used in qRTPCR.
Gene
Oct4
Sox2
Nanog
PolyA

Primer Sequence
Sense – GGTTCTCTTTGGAAAGGTGTTC
Antisense - ACACTCGGACCACGTCTTTC
Sense – AGGACTGAGAGAAAGAAGAAGAG
Antisense – AAGAAAGAGGCAAACTGGAATC
Sense – AATTCCCAGCAGCAAATCAC
Antisense - CCCTTCCCTCAAATTGACAC
Sense – AAGCAACTCCATCAACTACTG
Antisense - ACGGACTGGTCTTCATAGC

Amplicon
Length
223
215
164
169

Statistical Analysis
Statistical analysis was completed using SAS®. The statistical
significance of the experiment was set at P ≤ 0.05. A type 3 ANOVA was
performed to test for significant differences among the 6 treatments for each
pluripotency-associated gene, Oct4, Sox2, and Nanog. n-fold difference =
Efficiency Target GeneΔCTT/ Efficiency Reference GeneΔCTR
Table 4.2 P values for mean relative transcript levels of Oct4, Sox2 and Nanog
compared to controls in cells treated with zebularine for five days then cultured
for 14-16 days on Matrigel.
Gene
Oct4

P value
0.0160

Sox2

0.0221

Nanog

0.0065
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Gene Expression Ratios

Table 4.3 Mean relative transcript levels for Oct4, Sox2 and Nanog in control
treatment and cells treated with VPA or zebularine and/or infected with lentivirus
particles. Values marked with an asterisk (*) are different (P< .05) from the
control treatment for the corresponding gene.
Treatment

Oct4

Sox2

Nanog

Control

65.32033333

84.81746667

47.6419

VPA only

122.4062

4.95E+01

38.87443333

Zeb only

284.3566667*

182.5593333*

116.4466667*

VPA+Lentivirus

114.1696667

31.7363

31.65406667

Zeb+ Lentivirus

157.622

81.50066667

72.28906667

Lentivirus only

100.4565333

99.23946667

67.82446667

350
Con
VPA only
Zeb only
VPA+Virus
Zeb+Virus

300
250
200
150
100
50
0
4-Oct

Sox2
Nanog
Genes for each treatment group

Figure 4.1 Mean relative transcript levels (+/- SEM) for Oct4, Sox2 and Nanog in
control treatment and cells treated with VPA or zebularine and/or infected with
lentivirus particles.
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Results
There were differences in expression of Oct4, Sox2, and Nanog across
treatments of the cells (Table 4.2). Zebularine treatment along with the viral
infection resulted in an increase from the controls in Nanog (P=0.0592). Higher
levels of pluripotency-associated genes were achieved when using epigenetic
modifiers (Table 4.3); however, the gene expressions were highest with the use
of epigenetic modifiers rather than epigenetic modifiers with lentivirus. Use of the
lentivirus only resulted in higher expression ratio values when compared to the
control.
Discussion
Adipose-derived stem (ADS) cells are a desirable source of cells for stem
cell research because of their multipotent capabilities and ease of isolation
(Bunnel et al., 2008; Sun et al., 2009). They are a reliable source of large
quantities of cells that can be harvested from an individual (Gimble and Guilak,
2003). Reprogramming experiments aim to produce cells that are less
differentiated, can utilize ADS cells with hopes to improve reprogramming
efficiencies and avoid patient immune rejections. Reprogramming studies have
been performed on differentiated cells in nuclear transfer (Briggs and King, 1952;
Gurdon et al., 1958; Illmensee and Hoppe, 1981; Wilmut et al., 1997), direct
reprogramming with viral vectors (Takahashi and Yamanaka, 2006; Takahashi et
al., 2007; Wernig et al., 2007; Yu et al., 2007; Lowry et al., 2008; Carey et al.,
2009), fusion with ES cells (Cowan et al., 2005), and exposure to ES cell extracts
(Hochedlinger and Jaenisch, 2006).
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In this experiment, the reprogramming method of choice for the bovine
ADS cells was viral vectors. Cells treated for 5 days with epigenetic modifiers
were chosen for optimal expression of pluripotency-associated genes, Oct4,
Sox2, and Nanog (see Chapter 3). The ability of the lentivirus to reprogram the
cells was observed following treatment of the ADS cells with epigenetic modifiers
(VPA or Zeb) or without modifiers. The lentiviral vector contained transcription
factors for Oct4, Sox2, Klf4, and c-Myc. These factors are known as the
“Yamanaka four factors” based on their ability to produce iPS able to self renew
and differentiate into the three germ layers for 30 passages (Takahashi and
Yamanaka, 2006). The lentiviral vector utilized in this experiment was composed
of Addgene’s OSKM, PAX2, and MD2m.
Gene expression was variable among cell lines and treatments in this
experiment. When looking strictly at numerical data, zebularine treatment and
treatment with Zeb and lentiviral particles produced the highest increases in
pluripotency-associated genes. Oct4, Sox2, and Nanog were increased when
epigenetic modifiers and a combination of the epigenetic modifiers along with the
lentivirus was used.
Statistical differences for expression of the pluripotency-associated genes
were found for cells treated with Zeb. Zebularine treatment along with the viral
infection resulted in a significant increase in Nanog (P=0.0592). Zeb was able to
deplete DNA methyltransferase 1 with continuous treatment (Cheng et al., 2004),
and this ability to deplete DNA methyl transferase could be the reason in our
study why Zeb led to significant increases of gene expression. While Zeb was
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the only modifier to produce significant changes in this experiment, it has been
reported that VPA was the most efficient at assisting four-factor transduction,
resulting in a 100-fold improvement in reprogramming efficiency when compared
to the controls (Huangfu et al, 2008). A reason for the lack of a difference in
gene expression when using VPA alone is consistent with the finding that using
VPA treatment alone on cells does not induce ES cell properties (Huangfu et al.,
2008).
It was hypothesized that viral transduction in combination with epigenetic
modifiers would produce higher expression levels of the genes of interest, but
that was not the case in this experiment (Table 4.3). Although viral transduction
or treatment of the bovine ADS cells with epigenetic modifiers may produce
partial reprogramming, further investigation is needed to determine if complete
pluripotency was achieved. More cell lines should be utilized to increase the
power of the experiment. Induced cells also need to be examined for their ability
to produce teratomas in nude mice (Takahashi and Yamanaka, 2006). While this
study illustrated the ability of epigenetic modifiers and lentiviral transduction to
increase pluripotency-associated genes, this is only preliminary data in the
production of iPS cells able to be utilized in research for SCNT or clinical
research with regenerative medicine.
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CHAPTER V
SUMMARY AND CONCLUSIONS

Somatic cells were originally believed to possess irreversible cell nuclei
that could not reprogram from their determined cell type (Hochedlinger and
Jaenisch, 2006). However, this has was proven false with nuclear transfer
(Wilmut et al., 1997) and direct reprogramming with viral vectors (Takahashi and
Yamanaka, 2006). Differentiated cells can be reprogrammed to a pluripotent
state, where they have the ability to differentiate into all three germ layers of an
embryo. These cells can then be directed to differentiate into the desired cell
type when placed in certain culture conditions. These methods of producing
pluripotent cells are the driving force behind regenerative medicine because it
could produce patient specific cells that can regenerate or repair the patients
damaged or malfunctioning tissue. Although there is high potential with
reprogramming somatic cells with viral transduction, the reprogramming
efficiencies are very low with a reprogramming rate of less than 0.3% (Stocum
and Zupanc, 2008). In order to increase the reprogramming rate and help
decrease the need for known oncogenes (Klf4 and c-Myc) in the viral vector,
cells have been treated with epigenetic modifiers. Epigenetic changes refer to
heritable changes in gene function without causing a change to the DNA
sequence (Kiefer, 2007). Treating the cells with epigenetic modifiers can inhibit
the chromatin-modifying enzymes to reduce the chances of having incomplete
chromatin modification (Stocum and Zupanc, 2008).
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Bovine adipose-derived stem (ADS) cells were treated with one of two
epigenetic modifiers, valproic acid or zebularine, for 5, 7, 10, or 14 days to
observe the changes in pluripotency-associated genes (Oct4, Sox2, and Nanog).
This first experiment produced a significant difference in cells treated for 5 days
with either epigenetic modifier for Oct4 and Nanog. The treatments were found
to not be significant from each other. This partial reprogramming may result in
the bADS cells reaching complete pluripotency when combined with a
reprogramming technique. It has been reported previously that VPA can cause
histone acetylation and increase reprogramming rates when induced with
pluripotency factors (Huangfu et al., 2008; Zhou et al., 2009). VPA has also
been reported to be the most efficient at assisting four-factor transduction by
producing a 100-fold improvement on reprogramming efficiencies in MEF
(Huangfu et al, 2008). Furthermore, Zeb was observed to deplete DNA
methyltransferase 1 with continuous treatment (Cheng et al., 2004).
The second experiment combined the treatment of bovine ADS with the
epigenetic modifiers from experiment 1 followed by transduction of the cells with
a lentivirus. Statistical differences for expression of the pluripotency-associated
genes were found for cells treated with Zeb. Zebularine treatment along with the
viral infection resulted in a significant increase in only Nanog (P value of 0.0592).
As seen in the previous paragraph, VPA and Zeb should be able to cause the
desired epigenetic changes; however, the changes in pluripotency-associated
genes were variable in these experiments.
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Some improvements can be made in future experiments. More cell lines
should be utilized in to increase the power of the experiments. This would
hopefully produce more uniform and consistent data. Induced cells also need to
be examined for their ability to produce teratomas in nude mice (Takahashi and
Yamanaka, 2006). While epigenetic modifiers and lentiviral transduction have
been shown to increase pluripotency-associated genes, there is still a lot of
improvement and some changes that can be made to these experiments.
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APPENDIX: PROTOCOLS
Adipose-derived stem cell isolation:
1) Collect adipose tissue from each specimen and place in a wash solution
and maintain samples on ice
2) Under a hood, transfer tissue to a weighing boat and mince the tissue
3) Transfer minced tissue to a 50 mL conical tube and add 25 ml of wash
solution
4) Shake tube vigorously for 30 sec and allow phases to separate (about 5
min)
5) Carefully aspirate solution so not to remove any of the sample
6) Repeat wash, shake, and aspiration
7) Pour sample into a 150 ml Erlenmeyer flask (if sample does not easily
pour into the flask, remove using sterile forceps)
8) Add 15-20 mL of 0.25% collagenase solution (0.25% collagenase +1%
BSA (Fraction V) + PBS with Ca+ and Mg+
9) Add 200 µL of P/S and 200 µL of Fungizone to the flask containing the
tissue and collagenase solution
10) Cover flask with parafilm and place in shake incubator for 2 hours at 200
rpm at 37˚C
11) After incubation, transfer the entire suspension to a new 50 mL tube
12) Centrifuge 300xg for 5 minutes
13) Shake tubes vigorously for 30 seconds
14) Repeat centrifugation
15) Remove tissue from flask, leaving liquid in the tube and shake
16) Pour contents into a double filter syringe with a new 50 mL conical tube
receiving the filtered solution
17) Centrifuge at 300 x g for 5 minutes
18) Aspirate collagenase solution and resuspend in 15 mL of PBS with Ca+
and Mg+ +1% BSA (Fraction V)
19) Centrifuge at 300 x g for 5 minutes
20) Aspirate supernatant
21) Add 10 mL of DMEM + 10% FBA + 1% P/S + 2% Fungizone and
centrifuge for 5 minutes at 300 x g
22) Aspirate supernatant and resuspend cell pellet in 1 mL of culture medium
before placing in a flask
23) Add appropriate amount of culture medium to flask
24) Place in incubator
25) After 24 hours of culture, perform a primary wash and replace with 10 mL
of culture medium
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Cell Culture:
1) Use a Nalgene filter to filter cell culture medium (89mL DMEM, 10 mL Calf
Serum, and 1 mL Pen/Strep)
2) Vacuum out old medium from the flask
3) Wash with 5 mL of PBS without Ca+ and Mg+, then vacuum again
4) Add 0.5mL Trypsin for flask
5) Place the flask in the oven for 5 minutes
6) Add 5 mL of DMEM to flask to inactivate the trypsin. Rinse and suck
DMEM about 3 times, and move the liquid to a 15 mL tube for centrifuging
7) Centrifuge at 1200 rpm for 5 minutes
8) Vacuum out the DMEM and Trypsin leaving 1mL in the tube, and suspend
the cell pellet in the remaining 1mL
9) Add 90-99 L of PBS without Ca+ and Mg+ to a tube along with 10-1 L
or cell suspension
10) Add 10 L in each side of the Hemocytometer to count the cell
concentration.
Cell concentration equation = X/2/4 x 1(dilution factor) x 10,000
Amount of cells to add to new flask = amount of cells desired/ amount of cells
present x 1,000 = seeding density

Cryopreservation of Mammalian Cells:
1) Perform steps 1-10 of cell culture protocol
2) Determine the desired amount of cells to be frozen (usually no more than
1 million per vial
3) Make enough freezing medium (Calf Serum + 10% DMSO)
4) Centrifuge cells once again at 1200 rpm for 5 minutes
5) Vacuum off medium, and resuspend the pellet in 1mL of freezing medium
per vial
6) Place cryo vial in a cooled Mr. Frosty and place at -80˚C for 24 hours
before placing in liquid nitrogen
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mRNA Isolation from Cultured Cells using Dynabeads Oligo (dT)25:
Pre Wash Oligo Dynabeads:
1) Add 250 L of oligo dynabeads stock to a 1.5 mL tube
2) Put the tube in the magnetic separator for 30 seconds, and then remove
the supernatant.
3) Remove the 1.5 mL tube from magnetic separator and add 250 L of lysis/
binding buffer for washing the beads.
4) Put the tube back into the magnetic separator and remove the
lysis/binding buffer.
5) Add 250 L of lysis/ binding buffer and leave on the beads.
mRNA Isolation from cultured cells:
1) Remove old medium off of the target cells, and add trypsin for 5 minutes.
2) Centrifuge the trypsinized cells along with 5 mL of DMEM to form a cell
pellet.
3) Remove supernatant from the pellet, and wash with 1 mL of PBS. Move
the solution and resuspended pellet to a 1.5 mL tube.
4) Centrifuge in the little centrifuge for 1200 g (1.2 min-1) for 5 minutes.
5) Remove the supernatant and add 1250 L of lysis/ binding buffer. Vortex
for 10 seconds.
6) Strip the cells with a 21-gauge needle using a 1 mL syringe.
7) Centrifuge the samples at 12000g for 15 seconds.
8) Incubate the samples at room temperature for 10 minutes.
9) Add the pre-washed dynabeads to the sample, and put in the rotator for
10 minutes at room temperature.
10) Place the tube in the magnetic separator for 2 minutes.
11) Remove the supernatant, and wash the beads in 250 L of buffer A and
three times with buffer B.
12) RNA is eluted from the beads by adding 15 L of water and put in water
bath at 70C for 2 minutes.
13) Put the sample back into the magnetic separator and remove the
supernatant, which contains the RNA.
Converting mRNA to cDNA
cDNA Kit (iSCRIPT):
1) Move the 15 L containing the RNA into a PCR tube.
2) Add to the tube: 4 L of 5X buffer and 1 L of reverse transcriptase. If you
elute the RNA in 11 L, then you will need to add 4 L of nuclease free
water.
3) Put the PCR tube in the thermocycler with reverse transcription program
5 minutes at 25C
30 minutes at 42C
5 minutes at 85C
4) After the cycler has finished, the cDNA can be kept in the -80C freezer.
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Treating Bovine ADS cells with VPA or Zeb:
1) Day 1, plate cells with culture medium in 24 well culture dish. Fill 18 wells
in a 24 well dish (6 for control, 6 for VPA, and 6 for Zeb). Plate 50,000
cells in each well at passage 3
2) Day 2, change to trt media (6 for control, 6 for VPA, and 6 for Zeb)
3) Change media every 3 days until Day 5 and Day 7, 10, or 14
4) Isolate mRNA using above protocol
Control Culture Medium:
DMEM + 10% FBS + 1% P/S
TRT Culture Media:
1) DMEM +10% FBS + 1%P/S + 100 M Zeb
2) DMEM + 10% FBS + 1% P/S + 5mM VPA
50 mL of DMEM +10% FBS + 1%P/S + 100 M Zeb:
500 L Zeb stock
5 mL FBS
500 L P/S
44 mL DMEM
50 mL of DMEM +10% FBS + 1%P/S + 5mM VPA:
500 L VPA stock
5 mL FBS
500 L P/S
44 mL DMEM
ADS Cells Treated with VPA or Zeb Followed by Transduction with the
Lentivirus:
1) Day 1, plate cells with culture medium in 24 well culture dish. Fill 18 wells
in a 24 well dish (6 for control, 6 for VPA, and 6 for Zeb). Plate 50,000
cells in each well at passage 3
2) Day 2, change to treatment media (6 for control, 6 for VPA, and 6 for Zeb)
3) Change media every 3 days until Day 5
4) On Day 5, infect the cells (3 wells for each day from each trt) with lentiviral
particles
5) 3-4 days later, move to Matrigel coated dish (dishes coated with Matrigel
for 1 hour at room temperature before having the Matrigel solution
removed)
6) Once the cells from a colony, passage the cells 1-2 more times
7) Collect mRNA after colony formation
8) Isolate mRNA with Dynabeads using above protocol
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Producing the Lentiviral Vector:
Day 1:
1) Plate 7x105 HEK-293T cells in 5 mL of cell culture medium in 6 cm tissue
culture plate and incubate overnight at 37 C, 5% CO2 overnight
Day 2:
1) Late in the afternoon, in a polypropylene microfuge tube combine 1µg
pLKO.1 shRNA plasmid with 750 ng psPAX2 packaging plasmid, 250 ng
pMD2.G envelope plasmid, and 2 L serum-free OPTI-MEM
2) Each reaction will need 6 µL FuGENE® + 74µL OPTI-MEM, but add
OPTI-MEM first!
3) Incubate the tubes with 100µL volumes for 20-30 minutes at room
temperature
4) Add DNA:FuGENE® mix to cells drop wise and swirl to disperse
5) Incubate for 12-15 hours
Day 3:
1) Change the medium to remove the reagent
2) Replace with 5 mL of fresh culture medium
3) Incubate overnight
Day 4:
1) Harvest medium from cells and transfer to polypropylene storage tube
2) Replace with 5 mL of fresh culture medium
Day 5:
1) Harvest medium once again and spin this medium with the medium from
Day 4 to pellet any cells that were collected
2) Virus may be stored at -80˚C for long-term

Quantitative RT-PCR:
1) Using a 96 well plate for the reaction, master mixes should be made
2) 10 µL of SsoFast and 6 µL of nuclease free water per reaction should be
made into a master mix
3) Then a master mix of primers should be made using 2 µL of reverse and
forward primers per reaction
4) Last, the sample or calibrator cDNA needed should be added to each
reaction in the 96 well plate before being covered with sealing foil
5) PCR was performed using a LightCycler® 480 Instrument (Roche No.
04729692001).
6) Place plate in the LightCycler® 480 Instrument and run a denaturing cycle
of 30 sec at 95°C; 45 cycles of PCR (95°C for 5 sec and 55°C for 20 sec);
a melting curve analysis which consisted of 95°C for 5 sec, 65°C for 1 min,
followed by continuous acquisition at 97˚C, with 5 acquisitions per ˚C; and
a final holding temperature of 40°C
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